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Breast cancer is fast becoming the leading cause of mortality in women worldwide. As of
this year, there are more than 3.1 million women with a history of breast cancer in the U.S., and
about 41,760 women are expected to die from this disease. Neoadjuvant chemotherapy (NAC)
has become a well-established therapy in the treatment of patients with locally advanced or pri-
marily inoperable breast cancer. It consists of 3-9 months of drug treatment to shrink the tumor
size before surgical removal of any remaining mass. A pathological complete response (pCR) is
defined as complete disappearance of the tumor before surgery and correlates with 5-year overall
survival of the treated patient. However, only 15-40% of subjects who undergo NAC will achieve
a pCR, while the remaining patients do not benefit from a therapy that has considerable side ef-
fects. In this Ph.D. thesis, I explore the potential of diffuse optical tomography (DOT) for breast
cancer imaging and NAC monitoring. The overall objective is two-fold. First, I seek to identify
breast cancer patients who will not respond to NAC shortly after the initiation of a 5-9 months
therapy regimen. Identifying these patients early will allow a switch to a more promising therapy
and avoiding months of ineffective therapy with a drug regimen that has considerable side effects.
Second, I use the optical data simultaneously obtained from the contralateral, non-tumor bearing
breast to better understand the factors that modulate breast density and the source of its contrast
in DOT. This work analyzed DOT data from 105 patients with stage II-III breast cancer under
NAC regimen. Data processing and image analysis protocols were developed to more effectively
evaluate static tissue contrast and dynamic functional imaging of the breast. Notably, we observed
that there are differences in the time evolution of DOT features between pCR and non-pCR tu-
mors under NAC, and DOT features can contribute to the successful prediction of pCR status from
pretreatment imaging. Lastly, our analysis demonstrated a positive correlation between DOT fea-
ture and mammographic density classification, which could lead to research on the potential use
of DOT as a predictor of breast cancer as well as an assessment tool to longitudinally evaluate
the efficacy of chemoprevention strategies. These findings represent important steps towards the
translation of DOT into current clinical workflow to contribute to better-personalized breast cancer
therapies and breast cancer risk management.
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Chapter 1: Introduction and Background
1.1 General goals and specific aims
Breast cancer is fast becoming the leading cause of mortality in women worldwide. As of this
year, there are more than 3.1 million women with a history of breast cancer in the U.S., and about
41,760 women are expected to die from this disease [1]. In 2010, the cost of treating breast cancer
was about $16.5 billion in the U.S. alone, higher than any other type of cancer. This is expected
to increase to $20.5 billion by the end of 2020 [2]. Given the substantial impact on women and
the overall society, the last 30 years have seen substantial efforts towards a better understanding of
the fundamental causes of breast cancer, as well as new and efficient ways to diagnose, treat and
monitor the disease.
Medical imaging has long been an important part in diagnosing and monitoring breast cancer
[3] X-Ray mammography is still considered to be the gold standard for the early detection. It
has been shown that recently introduced digital breast tomosynthesis can increase the diagnostic
accuracy of mammography and is now increasingly used for the assessment of suspicious mammo-
gram findings [4]. Other modalities, such as ultrasound and contrast-enhanced magnetic resonance
(MR) imaging are also employed in the diagnostics, staging and follow-up of breast cancer. New
breast imaging modalities, such as contrast-enhanced spectral mammography, diffusion-weighted
MR imaging and MR spectroscopy are currently investigated for their potential to further improve
breast cancer diagnostics [5–7]. However, these new imaging methods are not yet routine used in
the clinical setting, and further studies are necessary to prove their advantages
In this PhD thesis, I explore the potential of diffuse optical tomography (DOT) for breast cancer
imaging. The overall objective is two-fold. First, I seek to identify breast cancer patients who
will not respond to neoadjuvant chemotherapy (NAC) shortly after the initiation of a 5-9 months
1
therapy regimen. Identifying these patients early will allow a switch to a more promising therapy
and avoiding months of ineffective therapy with a drug regimen that has considerable side effects.
Second, I use the optical data simultaneously obtained from the contralateral, non-tumor bearing
breast to better understand the factors that modulate breast density and the source of its contrast in
DOT. By investigating treatment-induced changes in the non-tumor-bearing breast, I will be able
to expand our research on tumor monitoring, to the area of breast-cancer risk assessment. To reach
these overall goals, I have pursued the following specific aims.
Specific Aim I: Development of new data processing and image analyses protocols to
more effectively evaluate static tissue contrast and dynamic functional imaging of the
breast.
Rationale: Currently available codes suffer from long and inefficient processing times.
Frequent intervention by the programmer is necessary to obtain reliable results.
Approach: New pre- and post-processing algorithms are proposed that allow for an
automated assessment of static tissue contrast and dynamic functional imaging. Using
a MATLAB GUI interface, I added important tools to automate data selection, data
filtering and mesh creation. Furthermore, I developed new ways for visualization of
the reconstructed images and tumor selection. This allows for better tracking hemo-
dynamic feature changes over time, and simplifies feature extraction. Standardization
for individualized meshes and data-set selection protocol were also implemented that
allow for more accurate longitudinal and inter-patient analyses.
Impact: Employing the new analyses tools enables the operator to more easily identify
areas of increased inflammation linked to malignant breast tumorigenesis. Quantifi-
cation of chemotherapy-induced changes in breast metabolism can be performed in a
fraction of the previously required time.
Specific Aim II: Conduction of a clinical study for monitoring breast cancer NAC for
tumor feature selection and construction of a model to predict the odds of a patient not
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having a complete pathological response to NAC.
Rationale: NAC has become a well-established therapy in the treatment of patients
with locally advanced or primarily inoperable breast cancer. It consists of 3-9 months
of drug treatment to shrink the tumor size before surgical removal of any remaining
mass. A pathological complete response (pCR) is defined as complete disappearance
of the tumor before surgery and correlates with 5-year overall survival of the treated
patient. However, only 15-40% of subject who undergo NAC will achieve a pCR,
while the remaining patients do not benefit from a therapy that has considerable side
effects. Therefore, predicting pCR early in the therapy is of great clinical interest
to avoid ineffective treatment. If non-pCR patient could be identified early, therapy
approaches could be changed.
Approach: In this retrospective study, NAC-induced total hemoglobin (ctTHb) dy-
namic changes, water percentage and lipid in the breast tumor region of 105 patients
will be evaluated for different chemotherapy drug combination, tumor subsets and
menopausal status. From the acquire data, I will extract optical features and combine
with pathological and patient information to model the odds of a patient not having a
complete pathologic response to NAC at the beginning of the regimen.
Impact: Designing a model to predict the odds of a patient not having a complete
pathological response to NAC. Identifying these patients early will allow a switch to a
more promising therapy and avoiding ineffective therapy with a drug regimen that has
significant side effects.
Specific Aim III: Investigation of chemotherapy-induced changes in the contralateral,
non-tumor bearing mass, and quantification of the breast tissue composition to provide
a comparable optical-based image index of mammographic breast density.
Rationale: In recent years, several groups have shown evidence that optical based
imaging modalities may play an important role in assessing breast tissue composition
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by measuring optical property contrast from endogenous chromophores. The advan-
tages of optical techniques are the use of non-ionizing radiation, ease of use, and
relatively low cost. Our team developed a so-called diffuse optical tomography breast
imaging system (DOTBIS) which does not require the use of contrast agents or com-
pression, and enables imaging of the whole volume for both breasts simultaneously
using low intensity near infrared light capable to measure tissue concentration of oxy-
hemoglobin (2C$21), deoxy-hemoglobin (2C1) and water percentage.
Approach: I hypothesize that diffuse optical tomography imaging provide quantitative
measurements of tissue functional components, such as 2C$21, which is directly
related to tissue metabolism and vascular characteristics, and could be correlated to
mammographic breast density, a known imaging biomarker of breast cancer risk.
Impact: There is a significant association between 2C$21, measured by DOTBIS,
and mammography breast density and this measurement is modifiable with potential
use as an imaging marker of breast cancer risk with the advantage of being 3D quantifi-
able, less dependent on accurate to positioning allowing for serial exams and without
exposure to ionizing radiation.
1.2 Breast Biology
The human breast, Figure 1.1, is a modified skin gland comprised of skin, superficial fascia,
breast parenchyma, nipple-areola complex and deep fascia [8]. The skin is the most superficial
layer of the breast. Right beneath the skin is the superficial fascia that envelops the breast and is
continuous with the superficial abdominal fascia [9]. The base of the undersurface of the breast lies
on the deep fascia of the chest wall and it is continuous with the deep abdominal fascia [10]. The
parenchyma contains a group of 15-20 lobes (large modified sweat glands), which are subsequently
composed of several lobules [8]. Each one of the lobules are surrounded by stromal tissue, a
connective tissue, that is highly cellular and susceptible to several hormones [11]. The breast also
contains an abundance of adipose tissue (fat), and its proportion, compared to glandular tissue,
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Figure 1.1: Schematic of sagittal view of the breast illustrating different types of fatty, fibrous, and
glandular tissue, and the different structures breasts are made of. Retrieved from J. R. Harris et al.,
Diseases of the Breast (fig. 1.2, p. 4) [9]
increases with age reaching its maximum amount in the postmenopausal stage [8, 12].
The breast structure and function are strongly responsive to the cyclic changes in the reproduc-
tive hormonal events. Not only in pregnancy, the human breast is expecting to reflect the regular
periodic cycling of ovarian estrogen and progesterone secretion during the menstrual phase [13].
The four main phases of the menstrual cycle include: i) menstruation, ii) the follicular phase, iii)
ovulation, and iv) the luteal phase. The changes in breast cellular growth rates are associated to
both follicular and luteal phases. The main proliferative phase is the mid-luteal phase (between
days 15-28) of the menstrual cycle, during which time progesterone and estrogen levels are both
high [14]. An increased blood flow in the premenstrual breast, due to the higher proliferation in the
luteal phase, elicits an average increase in the breast volume of 15 to 30 2<3 [9]. Through the end
of the cycle and the beginning of menstruation, the breast epithelium regresses by apoptosis [15]
with minimum breast volume observed between days 5 and 7. Consequently, with the permanent
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termination of the menstrual cycle due to the reduction of hormonal production in the menopausal
stage (between the ages of 35 and 60), the breast connective tissue regresses and it is replaced by
fat [16].
Figure 1.2: Vascular supply of the breast. Retrieved from J. R. Harris et al., Diseases of the Breast
(fig. 1.3, p. 5) [9]
In addition, another important aspect from the breast biology is the vascular anatomy. In agree-
ment with the reduction fibroglandular tissue after menopausal, premenopausal women tend to
have more blood volume in the breast than postmenopausal ones, with the largest concentration
of blood vessels in the nipple region. The breast receives its blood supply from different sources:
i) internal mammary (thoracic) artery, ii) axillary (lateral thoracic and thoracoacromial) arteries
and, iii) intercostal arteries, as shown by Figure 1.2. The internal mammary artery is the main
blood supplier, which supply the medial and central breast parenchyma [17]. Venous drainage of
the breast is mainly through the axillary vein and the internal mammary veins, and in deep breast
tissue, is paired with the arterial anatomy. In contrast, superficial veins do not follow the arterial




Breast cancer is by far the most common and frequent cause of cancer death in the U.S, Table
1.1. For American women, it’s estimated that about 30% of newly diagnosed cancers will be breast
cancer. The highest incidence of breast cancer is in middle-aged and older women (mean age at
diagnosis is 62), Figure 1.3. However, young breast cancer patients (≤ 35 years old) have a higher
risk of dying, worse disease-free survival, and lower overall survival compared to the middle-age
and older women, [18, 19].
Table 1.1: Common Types of Cancer: Number of New Cases and Deaths. Retrieved from http:
//seer.cancer.gov/statfacts/html/breast.html.
Common Types of Cancer Estimated New Cases 2020 Estimated Deaths 2020
Breast Cancer (Female) 276,480 42,170
Lung and Bronchus Cancer 228,820 135,720
Prostate Cancer 191,930 33,330
Colorectal Cancer 147,950 53,200
Melanoma of the Skin 100,350 6,850
Bladder Cancer 81,400 17,980
Non-Hodgkin Lymphoma 77,240 19,940
Kidney and Renal Pelvis Cancer 73,750 14,830
Uterine Cancer 65,620 12,590
Leukemia 60,530 23,100
Breast cancer is more common in African-American women under 45 than white women.
Overall, however, black women have a lower incidence rates than white women. Yet, based on
SEER cancer statistics facts [20], African-American women are more likely to die of breast cancer
(Figure 1.4). The reason appears to be that diagnoses are often made at later stages of the disease
and high incidence of triple negative breast cancer (an aggressive subtype of breast cancer linked
to poorer survival) in this particualr population [8]. Asian, Hispanic, and Native-American women
all have lower risk of developing and dying from breast cancer than white or African-American
women.
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Figure 1.3: Percent of New Cases by Age Group. The highest incidence of breast cancer di-
agnoses is at an age of 55-64. Retrieved from http://seer.cancer.gov/statfacts/html/
breast.html.
1.3.2 Risk factors
The biggest risk factor for breast cancer is just being a female [12]. The established risk factors
that have been associated with an increased risk of developing breast cancer are [21]: advanced age,
genetic mutations, reproductive history, dense breasts, personal history of breast cancer or certain
non-cancerous breast disease, family history of breast cancer, previous treatment using radiation
therapy, and previous treatment with diethylstilbestrol (DES).
The incidence of breast cancer is directly proportional to age. [22]. The majority patients are
diagnosed after the age of 50, and less than 0.3% of the cases occur in patients under 30 years of
age. Women with inherited mutation in BRCA1 and BRCA2 genes (tumor suppressor genes) have
up to 70% risk of developing breast cancer [23]. Breast cancer that is positive for the BRCA1 or
BRCA2 mutations account for 5%-10% of all female breast cancers [24].
One of the most established imaging biomarkers of breast cancer risk is mammographic breast
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Figure 1.4: Female breast cancer mortality rates between 2011-2015. African-American women
are more likely to die of breast cancer then white women in U.S. Retrieved from http://seer.
cancer.gov/statfacts/html/breast.html.
density [25–27]. Women with dense breasts have higher risk of breast cancer than women with less
dense breasts [28, 29]. For instance, women in the most dense category (proportion of dense fi-
broglandular tissue within the total area of the breast (PID) ≥ 75%) have more than 4 times the risk
of developing breast cancer compared with the least dense category (PID < 5%) [20]. Breast den-
sity is influenced by genetics, and has shown to change with age, body weight, menopause status,
pregnancy and certain drug, such as tamoxifen, and medication used in hormone therapy [30–33].
According to the Breast Imaging Reporting and Data System, or BI-RADS, mammographic breast
density is classified into 4 categories, which goes from almost all fatty tissue to extremely dense
tissue and almost no fat, Figure 1.5. The biologic mechanism by which mammographic breast
density is associated with an increased risk of breast cancer, however, remains no conclusive.
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Figure 1.5: Breast density categories. Adapted from “Breast density and your mammogram” by
American Cancer Society. Retrieved from http://www.cancer.org/cancer/breast-cancer/
screening-tests-and-early-detection/mammograms.html.
1.3.3 Types of Breast Cancer
Breast cancers is not a homogenous disease, and is typically classified into several subtypes
based on the tumor pathology and molecular profile [34]. Based on the tumor histopathological
characteristics, breast cancer can be classified as in situ or invasive carcinoma. There are two
further sub-classifications for in situ breast cancer: ductal carcinoma in situ (DCIS) and lobular
carcinoma in situ (LCIS). DCIS, which constitutes approximately 5% of breast cancers, is charac-
terized by the proliferation of abnormal cells from the mammary ductal epithelial cells still con-
tained by a basement membrane [35]. On the other hand, LCIS, a rare form of mammary cancer,
is characterized by proliferation of abnormal cells within the lobules of the breast [36, 37].
From U.S. breast cancer statistics [38], 48,530 new cases of in situ breast cancer are expected
in 2020. However, the invasive one is the most commonly diagnosed type of breast cancer, and
alone accounts 80% of new diagnoses (with an estimated 276,480 new cases in 2020). Invasive (or
infiltrating) breast cancer is characterized by the proliferation of abnormal cells in the surrounding
tissue of the milk ducts, known as invasive ductal carcinoma (IDC), or glands, also referred to
as invasive lobular carcinoma (ILC). It is important to highlight that IDC is the most common
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types of breast cancer (about 8 of 10 invasive breast cancers are IDC), however there are other less
common types, such as inflammatory breast cancer, Paget disease of the nipple, phyllodes tumor,
and angiosarcoma, and a single breast cancer diagnoses can be a combination of different types of
carcinoma [39].
In addition, there are at least four distinct molecular subtypes of breast cancer, which differ
according to their hormone (estrogen or progesterone) receptor (HR+/HR-) status and human epi-
dermal growth factor receptor 2 (HER2) expression [40]. Evaluation of theses biological markers
are essential in daily clinical practice since different subtypes have different outcomes, responsive-
ness to treatment and risk profiles. The intrinsic subtypes of breast cancer are described below [22].
Furthermore, the incidence rates of female breast cancer by subtypes and race/ethnicity between
2010-2014 in the U.S. is shown by Figure 1.6.
Luminal A (HR+/HER-)
• Slow growing and less aggressive;
• Favorable prognosis;
• More responsive to anti-hormonal therapy.
Luminal B (HR+/HER2+)
• Like luminal A cancers, luminal B are estrogen receptor positive (ER+) and/or progesterone
receptor positive (PR+);
• Highly positive for Ki67 (indicator of a large proportion of actively dividing cells);
• Higher grade and poorer survival rates than Luminal A cancers.
Triple negative (HR-/HER2+)
• Twice as common in black women as white women in the US;
• More common in premenopausal women and those with a BRCA1 gene mutation;
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• Poorer short-term diagnosis;
• No target therapies available for these tumors.
HER2-enriched (HR-/HER2+)
• Grow and spread more aggressively;
• Short-term prognosis compared to HR+ cancers;
• Target therapies available.
Figure 1.6: Female breast cancer incidence rates by subtype and race/ethnicity between 2010-
2014 in U.S. Retrieved and adapted from “Cancer Stat Facts: Female Breast Cancer” by SEER.
Retrieved from https://seer.cancer.gov/statfacts/html/breast.html.
The ER, PR and HER2 status is also used for cancer staging to help plan treatment. The staging
process provides an effective way to express the severity of patient’s cancer based on the magnitude
of the primary tumor and if or where it has spread. The most commonly used method is the TNM
Staging System proposed by the American Joint Committee on Cancer (AJCC) and the Union for
International Cancer Control (UICC). According to their manual [41], this system is based on the
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extent of the tumor (T), the extent of spread to the lymph nodes (N), and the presence of metastasis
(M). Table 1.2 summarizes the T, N and M categories for breast cancer. Once all these factors are
determined, they are combined, and an overall stage of 0, I, II, III, IV is assigned.
1.3.4 Treatment
For early breast cancer treatment, the management plan takes into consideration the molecular
subtype, since different molecular subtypes differ in terms of response to treatment, and also tu-
mor load (number of cancer cells, the size of a tumor, or the amount of cancer in the body) [42].
Breast cancer treatment can be divided into local (surgery and radiation) and systemic (chemother-
apy, hormone therapy, targeted therapy and immunotherapy). For in situ breast cancers, surgery
followed by radiation or hormone therapy is usually adopted. On the other hand, invasive breast
cancer will be treated with some type of surgery combined with other treatments, such as radiation,
chemotherapy, hormone therapy or target therapy, to reduce the risk of recurrence and improve
overall survival. For metastatic breast cancer, systemic therapy is the primarily treatment option.
Within the systemic therapy approach, neoadjuvant chemotherapy (NAC) - delivered before
definitive breast cancer surgery - has emerged as the standard treatment for primary operable and
locally advanced breast cancer [43]. It was introduced in the late 70’s, when it was first shown
to reduce tumor size in patients with locally advanced and inflammatory breast cancer [44]. This
allowed for breast conservation surgery as an alternative to radical mastectomy. Clinical trials,
performed 20 years later, then revealed that in addition to conservation surgery, long-term rates of
distant tumor control were comparable with those obtained with standard adjuvant chemotherapy
therapy, a therapy given after surgical intervention [45–47]. Furthermore, it was discovered that
the neoadjuvant setting provided a prognostic marker for long-term outcome. Additional clinical
studies performed over the last 10 years have confirmed the advantages of NACT and the preoper-
ative introduction of chemo-therapeutic regimens has become standard clinical practice [48–52].
Patients with a so-called pathological complete response (pCR), defined as the absence of residual
invasive disease after NACT in the breast, lymph nodes, or both, had a superior outcome when
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Table 1.2: T, N and M categories for breast cancer. Retrieved and adapted from “Breast Can-
cer Stages” by American Cancer Society https://www.cancer.org/cancer/breast-cancer/
understanding-a-breast-cancer-diagnosis.html.
Primary Tumor (T)
TX Primary tumor cannot be assessed.
T0 No evidence of primary tumor.
Tis Carcinoma in situ (DCIS, or Paget disease of the nipple with no associated tumor mass).
T1 Tumor is 2 cm (3/4 of an inch) or less across.
T2 Tumor is more than 2 cm but not more than 5 cm (2 inches) across.
T3 Tumor is more than 5 cm across.
T4 Tumor of any size growing into the chest wall or skin. This includes inflammatory breast
cancer.
Regional Lymph Nodes (N)
NX Nearby lymph nodes cannot be assessed (for example, if they were removed previously).
N0 Cancer has not spread to nearby lymph nodes.
N1 Cancer has spread to 1 to 3 axillary (underarm) lymph node(s), and/or tiny amounts of
cancer are found in internal mammary lymph nodes (those near the breast bone) on sen-
tinel lymph node biopsy.
N2 Cancer has spread to 4 to 9 lymph nodes under the arm, or cancer has enlarged the internal
mammary lymph nodes.
N3 The cancer has spread to 10 or more axillary lymph nodes. Or it has spread to the lymph
nodes located under the clavicle, or collarbone. It may have also spread to the internal
mammary lymph nodes or to the lymph nodes above the clavicle.
Distant Metastasis (M)
MX Distant spread (metastasis) cannot be assessed.
M0 No distant spread is found on x-rays (or other imaging tests) or by physical exam.
M1 Cancer has spread to distant organs (most often to the bones, lungs, brain, or liver).
compared with patients with residual tumor at the time of surgery. The residual cancer burden
(RCB) achieved after NAC reflects response to therapy and predicts overall survival and disease-
free survival [53–55]. RCB scores, defined by Equation 1.1, are based on combining pathologic
measurements of primary tumor (size and cellularity) and nodal metastases (number and size) [56]:
58=E is the proportion of the primary tumor bed that contains invasive carcinoma, 31 and 32 are the
bidimensional diameters of the primary tumor bed in the resection specimen, !# is the number
of axillary lymph nodes containing metastatic carcinoma, and 3<4C is the diameter of the largest
metastasis in an axillary lymph node. A person is considered to have a pCR if RCB ≤ 0.5 (RCB
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class 0). The RCB score is further classified as RCB I (0.5 < RCB ≤ 1.36), RCB II (1.36 < RCB
≤ 3.28), and RCB III (RCB > 3.28). Patients identified as belonging to RCB III are the least
















The current chemotherapy standards in preoperative treatments are anthracycline-based and
taxane-based therapies, and they are particularly recommended to triple-negative and HER2+
breast cancer. As recently showed by many groups, the pCR rates after NAC are highly depend-
able on tumor subtype [57–60]. In a study published in 2014 it was discovered that the association
of event free survival is highest in TNBC patients and HER2+ tumors [61]. The 3-year overall
survival TN breast cancer patients with pCR was found to be 94% compared to 68% without pCR.
The 5-year survival of patients with HER2+ tumors with pCR was 95% compared to 65% without
pCR. On the other hand, pathologic response to slowly proliferative tumors, such as HR+ luminal
A and B, did not associate with prognosis and was not considered a suitable surrogate endpoint.
Another, more recent study [62], found that patients with HER2+ cancer who received HER2-
targeted therapies and showed a pCR had a 10-year-relapse-free-survival rate of 95% compared
to only 50% if a pCR was not achieved. For patients with TN breast cancer who had a pCR the
10-year-relapse-free-survival was 86% compared to 53% for patients without a pCR.
Although NAC alone can lead to pCR rates of 15% to 60% [56, 63–65], response rates in pa-
tients with HER2+ and TNBC are usually higher than rates observed in patients with luminal A and
B tumors. With these latest findings, the neoadjuvant setting is now promising to becoming a place
for tailoring individual treatments. If in addition to breast cancer subtypes, physicians can predict
treatment outcome (e.g. will patient have a pCR or not) early in the therapy (e.g. a few weeks after
treatment initiation) an ineffective therapy with substantial side effects (such as hair loss, severe
diarrhea, nausea and vomiting, mouth sores, peripheral neuropathy, pain in the joints and muscles)
could be avoided. Even more importantly, different treatment regimens that may be more effective
could be pursued. For example, NIH alone is currently supporting over 20 different neoadjuvant
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clinical studies, which test various combinations of new drugs; and, indeed, several recent stud-
ies have shown that changing therapy in patients that do not show an early response may benefit
from a change in treatment regimen [66–71]. The FDA has recognized this opportunity and issued
guidelines that the neoadjuvant setting is an opportune setting for clinical investigation in popula-
tions in which pathologic response predicts survival, such as HER2+ and TNBC. For instance, an
improved pathologic response can lead to accelerated drug approval for newly developed targeted
agents, such as pertuzumab for HER2+ breast cancer. In July 2016, two simultaneously released
articles with different novel agents evaluated in the I-SPY2 trial were reported in the New Eng-
land Journal of Medicine [50, 51, 72]. In an accompanying editorial, the focus was on how the
NACT can be a setting for a quicker means of drug assessment and approval [73]. In these stud-
ies, as well as a number of the many ongoing NIH-sponsored neoadjuvant clinical trials, the new
drugs are tested in combination with a standard taxane-anthracycline backbone. In the most recent
practice-changing, the KATHERINE trial, patients with residual disease after standard NAC and
HER2-targeted therapy benefited from switching systemic therapy [71]. In response, an editorial
from the FDA commented on how the post-NAC setting for patients with residual disease may also
be a regulatory pathway for drug development and approval [74].
1.4 Breast Imaging
Imaging of breast cancer plays a significant role in the primary screening of cancer and risk
assessment. Various imaging modalities are also employed to characterize breast lesions (e.g.
benign versus malignant), monitoring the response to treatment, and in determining breast cancer
recurrence. In the following, I will discuss the major methods currently in use.
1.4.1 Mammography
Mammography is the most common method of breast imaging. It is widely available and
standardized quality measures have been developed. However, its sensitivity is limited, and mam-
mography misses about 13% of breast cancers [75]. This approach is even less accurate in women
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having dense breast tissues [76, 77]. Still, mammography remains the widely used screening tool
for the early detection of breast cancer, and has helped reducing breast cancer mortality rate by
25% - 35% in screened women when compared with a control group after 2 to 9 years of follow-up
[78–80].
As mentioned, one of the main factor that affects mammographic screening is breast density.
High breast density is one of the main reasons for the low specificity. Furthermore, it is an inde-
pendent risk factor for breast cancer. Women with dense breasts have higher risk of breast cancer
than women with less dense breast in the same age group. This risk remains increased for at least
a decade after the first mammographic breast density examination was performed [81]. However,
mammography has not been adopted for breast density quantification on breast cancer risk assess-
ment due its limited ability to quantify longitudinal density variations accurately and its use of
ionizing radiation restricts frequent screening ofer long time periods.
1.4.2 Ultrasound
Ultrasound imaging has emerged as a critical supplemental breast cancer imaging tool, because
it overcomes some of the limitations of mammography. For example, in cases of dense breast tis-
sue, ultrasound imaging increases the cancer detection rate and improves overall sensitivities in
breast screening [82–84]. Ultrasound has also found to be useful in differentiating benign and
malignant lesions, improving preoperative tumor staging and guiding needle biopsies [85]. Since
different signal intensities between fibroglandular and fatty tissue can be detected by ultrasound,
some groups have argued that ultrasound might also be useful in assessing breast density. Correla-
tion ranging from r = 0.65 to 0.74 between ultrasound- and mammography-derived breast density
measurements have been found. However these studies were to small to establish statistical signif-
icance. [86–88]. Additional clinical studies are needed for validating the use of US for assessing
breast density and cancer risk [89].
The use of breast ultrasound imaging to assess the effectiveness of NAC and predicting the
response of primary tumors to chemotherapy are also discussed in literature. Over the past 5
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years, Czarnota’s group has presents several studies on this topic. In his most recent work, which
included 96 patients, they combined quantitative ultrasound parameters with molecular features.
With this approach they were able to predict treatment response with an accuracy of 78% after
first week, and 86% at week four after treatment [90]. In another study, Yang’s et al demonstrated
association between percentage change in tumor ultrasound measurements at mid-treatment and
RCB scores in triple negative and HR+/HER2- cancers [91]. Forsberg’s group proposed the use
of three-dimensional subharmonic aided pressure estimation and subharmonic imaging for moni-
toring patients under NAC. In a pilot study with 8 subjects, they demonstrated that subharmonic
signal increased more in the tumor than in the surrounding area for responders compared with
non-responders at completion of 10% of therapy [92]. In the most recent publication on this topic,
researchers found statistically significant differences between responders and non-responders after
three NAC courses (overall accuracy of 82).% [93]. This study involved 24 breast cancer patients.
These findings suggest that it may possible to use breast ultrasound to evaluate the early tumor re-
sponse to NAC. However larger cohorts of patients are needed to verify whether these preliminary
observations are significant.
1.4.3 Digital Breast Tomosynthesis
Digital breast tomosynthesis (DBT) has become an important tool in clinical practice since
its approval by the U.S. Food and Drug Administration in 2011. It has been shown that DBT
reduces the negative impact generated by the superimposition of structures in the breast, which
can obscure malignant tumors in the mammography screening. [81]. Based on the first large-scale
DBT screening studies [94–98], adding tomosynthesis was associated with a decrease in recall
rate and an increase in cancer detection rate with greatest potential value in women with dense
breast tissue. However, current available clinical data remain insufficient to recommend DBT for
screening or diagnosis, and long-term follow up is needed to determine its impact on breast cancer
mortality. Furthermore, tomosynthesis requires twice the total radiation dose as compared to the
current digital mammography alone. [99], and increases interpretation time for the radiologists
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[100].
Besides being used for improvement of cancer detection and confidence, studies have been
exploring DBT’s use for the measurement of breast density [101–106]. In the largest study to
date (n=9909), the Malmö Breast Tomosynthesis Screening Trial (MBTST) analyzed quantitative
volumetric breast density agreement in mammography and DBT [107]. The study reported a high
correlation between volumetric breast density in mammography and DBT, and moderate agree-
ment between radiologists’ BI-RADS scores and density categories assessed from mammography
and DBT. However, breast density values measured with DBT were underestimated in a non-linear
relationship across the four BI-RADS categories when compared to breast density on mammogra-
phy [108]. Therefore, as pointed out by Tagliafico et al, not having a correction factor to compare
breast density assessed from DBT and mammography might underestimated breast cancer risk
prediction values when breast density is available only from DBT images [109].
1.4.4 Dynamic contrast-enhanced MRI
Functional imaging techniques to assess breast cancer in all its diversity has also been explored,
as a method that may overcome mammography’s sensitivity limitations and its low efficacy in
dense breasts. Dynamic contrast-enhanced MRI (DCE-MRI) offers measurements of tissue perfu-
sion and permeability, in addition to breast anatomical high resolution information.
From DCE-MRI models, microcirculatory parameters such as perfusion, blood volume, mean
transit time, and vessel permeability parameters can be derived from the kinetics of signal variation
in breast lesions after contrast agents (eg. Gadolinium) administration. By measuring properties of
tissue microvasculature, DCE-MRI provides potential biomarkers for tumor response to ANTI(??)-
angiogentic chemotherapy treatments [110].
The quantitative analysis of DCE-MRI includes nonparametric (model free) and parametric
(analytical) techniques [111]. By acquiring baseline images followed by a series of images during
and after the arrival of the contrast agent, a time intensity curve for the breast tissue is generated,
which correlates to the contrast agent concentration in the tissue. Non-parametric quantification,
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easy to calculate, is derived directly from the shape of the signal intensity curve (e.g. wash-in
slope, AUC, maximum enhancement, and time-to-peak). On the other hand, parametric analy-
sis derive quantitative tissue parameters (e.g. capillary permeability and volume fraction) from
converting the MR signal intensities into contrast agent concentration measurement, and fitting
pharmacokinetic model to the concentration curve. These models can be categorized in two main
groups, compartmental models [112, 113] and spatially distributed models [114, 115].
While DCE-MRI provides high-resolution morphologic and functional information, it still
lacks a standardized protocol, and low reproducibility and repeatibility have been reported, es-
pecially for longitudinal studies [116, 117]. Other important drawbacks include its high-cost and
contraindications to women with severe clastrophobia, metalic implants or allergic reaction to con-
trast agents [118].
1.4.5 Diffuse Optical Tomography
In recent years, several groups [119, 120] have produced evidence that optical-based imaging
modalities may play an important role in assessing breast tissue composition by measuring optical
contrast from endogenous chromophores within near-infrared (NIR) and visible light range (400
- 1000 nm). The advantages of optical techniques are the use of non-ionizing radiation, ease of
use, and relatively low cost. Exploiting optical properties of tissues for structural changes and
functional abnormalities identification are dated from the 1990’s [121].
The very first attempts to use visible light in the differential diagnosis of breast lesions were
reported by Culter in 1929 [122]. His team used transillumination, Figure 1.7, which was easy
to perform. But as pointed out by clinical studies in the 1980’s, it showed lower sensitivity and
specificity when compared to x-ray mammography [123, 124], and the method was not able to
differentiate between scatter and absorption of the tissue [125].
Starting in the 1990’s, some modelling and reconstruction methods for optical imaging were
proposed to overcome the nonlinear inverse problem for recovering intrinsic optical parameters
from boundary measurements of transmitted and/or reflected light [126]. In other words, these
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Figure 1.7: Transillumination records for the breast published by Culter in 1931 [122]. Left:
Normal breast. Center: Solid tumor in the breast. Right: Breast hematoma. As highlighted by
the author, solid tumors are opaque to transillumination since the opacity of blood is intense and
different from a cyst filled with a clear fluid.
methods should be able to model the propagation of photons in highly scattering media and recon-
struct images out of a finite number of surface measurements. DOT technology relies on the fact
that important tissue characterization chromophores such as hemoglobin, water and lipid have low
absorption at the NIR range (650 to 950 nm) then light can easily propagate through several cen-
timeters, and the wide variety of ways different tissues absorb and scatter light. Therefore, DOT
imaging performance is a reflection of existing differences in the optical properties for distinct
endogenous chromophores, which allow the contrast between healthy and diseased tissue.
The propagation of electromagnetic radiation in an absorbing and scattering medium is mod-
eled by a simplified version of the Maxwell’s Equations for analysis and calculation of photon
transport, the radiative transport equation (RTE). Assuming (1) the average distance of propaga-
tion between photon absorption and scattering events is significantly larger than the wavelength of
light, (2) the light is unpolarized in the medium of propagation, and (3) constant propagation ve-
locity for light in the medium, RTE can accurately model the migration of photons through human
tissue [127]. However, solutions to the RTE require computationally intensive numerical meth-
ods [128]. By considering light propagates approximately isotropically throughout an isotropic
medium, RTE can be simplified to a a diffusive approximation (DA) model of photon propagation.
In summary, DA equation depends on only the light source, the absorption and reduced scattering
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coefficient, and data is acquired by introducing light from a source into tissue, measuring it at given
detector positions, and solving an inverse problem to calculate the optical properties of the tissue
under study.
Optical breast imaging technologies can be divided according to the temporal profile of the
laser radiation employed for data acquisition [129]:
• Time Domain (TD): Characterized by high spatial and depth resolution, TD systems detect
short laser pulse shape after propagating through tissue, and both absorption and reduced
scattering coefficients may be derived from analysis of the detect light using a model of
photon propagation.
• Frequency Domain (FD): Less accurate, but faster and cheaper than TD systems, FD tech-
nique uses intensity-modulated laser to excite chromophores, and calculates absorption and
scattering coefficients by measuring light demodulation and phase shift.
• Continuous Wave (CW): Low cost technique, CW systems use continuously emitting light
sources to measure the average attenuation coefficient of the light detected after propagating
through the medium, which is a combination of the scattering and absorption coefficient.
Potential applications of diffuse optical imaging include diagnosis [130–133], monitoring tu-
mor response to NAC [134–143], and assessment of breast density [125, 144–148]. However,
larger studies are necessary to integrate DOT technologies to the clinical routine and, to play a key
role in breast cancer precision medicine.
1.5 Overview of this Thesis
The primary objective of this thesis is to assess the potential clinical utility of DOTBIS in breast
cancer imaging and treatment monitoring. To this end, I examine changes in optically derived
parameters in the tumor volume and the contralateral unaffected breast in patients receiving NAC.
The remainder of this thesis is organized as follows.
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Chapter 2 describes the clinical study population and design for longitudinal static and dynamic
data acquisition. DOTBIS measuring and imaging protocol are explained in details. Schematics of
the graphical user interface implemented to automatize data processing and feature selection are
presented. In addition, reconstruction results were compared to a multimodal optical molecular
imaging open source software for validation purposes, and the results are shown in Section 2.4.
Characteristics of the patient cohort enrolled for this longitudinal clinical study are summarized in
Section 2.5.
The next three chapters present results from static data analysis. Chapter 3 shows the analysis
for the data acquired from the breast bearing the tumor. Chapter 4 presents the study results from
the contralateral non-affected breast. And, Chapter 5, by using baseline measurements from the
contralateral non-affected breast, provide a comparable optical-based image index of mammogra-
phy breast density.
Chapter 6 explores the potential behind hemodynamic features and its impact in offering pre-
treatment prediction (at baseline) of tumor response to NAC.
The last chapter provides a summary of the most important results. In addition, commentary is
provided on the potential of DOTBIS and future directions of the thesis work.
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Chapter 2: Study Design and Methodology
2.1 Data acquisition
In this study, 105 patients with stage II-III breast cancer were prospectively enrolled in an
Institutional Review Board (IRB)-approved clinical protocol at Columbia University Irving Med-
ical Center between 2011 and 2019. Each patient received a taxane-based regimen. Pathologic
response, as defined by Symmans et al. [56], was dichotomized, with pCR defined as complete
absence of invasive carcinoma in the breast and lymph node(s) (ypT0/is ypN0 Mx) at the time of
surgery. Menopausal status, age and BMI were recorded in the patient’s electronic medical record
and retrieved for this work.
Sixty-nine patients received 12 cycles of weekly paclitaxel (with or without an addition of
carboplatin) followed by 4 cycles of doxorubicin and cyclophosphamide given every 2 weeks with
growth-factor support (T x 12/AC x 4 or T/C x 12/AC x 4), and DOTBIS bilateral measurement
were acquired at six different time points: before starting NAC regimen (baseline); after two weeks
of taxane infusions (TP1); after four weeks of taxane (TP2); at the end of the taxane regimen
and before starting AC cycles (TP3); after two cycles of AC (TP4); and at the end of NAC and
before surgery (TP5). Thirty-six patients received other taxane-based NAC regimens without an
anthracycline, and bilateral imaging was performed only three times (baseline, 2-3 weeks after the
first taxane infusion (TP1) and at the end of NAC and before surgery (TP5)), as illustrated in Figure
2.1
Measurements were performed by a continuous wave dynamic imaging system (i.e., DOTBIS),
Figure 2.2, that provides full three-dimensional tomographic images of both breasts simultaneously
without requiring the use of contrast agents or compression. Patient interface consists of two sets
of four rings that uses up to 32 sources and 64 detectors, depending on patient’s breast cup size, for
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Figure 2.1: DOTBIS bilateral measurement were acquired at six or three different time points
depending on NAC regimen. For patients under Tx12/ACx4 and T/Cx12/ACx4 therapies (n=69),
contralateral non-tumor-bearing breast and the breast bearing the tumor were imaged at baseline
(TP0); two weeks after the first taxane infusion (TP1); after four infusions of taxane (TP2); at the
end of the taxane regimen and before starting AC cycle (TP3); after two AC infusions (TP4); and
at the end of NAC and before surgery (TP5). For other taxane-based NAC regimens (n=36), both
breasts were imaged only three times: TP0, 2-3 weeks after the first taxane infusion (TP1) and
TP5.
optical data collection. A more detailed description of the system can be found in previous reports
[149, 150]. Total measurement time varied between 8 to 10 minutes in addition to 5 minutes
required to set up the machine. Imaging begins with a baseline measurement of about 2 minutes.
Next, the patient is instructed to hold her breath for 30 seconds and then given 90 seconds to
recover. Each patient performs 3 breath holds. Once the patient imaging is done, a calibration
measurement is performed with a reference solution, which is composed of well-defined mixtures
of intralipid and india ink with optical properties similar to breast tissue.
2.2 Data pre-processing
Data was analyzed using customized MATLAB scripts (The MathWorks, Inc., Natick, USA).
The following text contain in detail all the major features developed to automate the analyses of
static tissue contrast and functional imaging acquired from the DOTBIS imager.
Figure 2.3 shows a screen shot of the MATLAB graphical user interface (GUI) implemented
to automatize data selection, filtering and mesh creation. The windows of the lower panel provide
visualization of the patient’s raw data for the left and right breasts (1). This set up also allow us
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Figure 2.2: Left: photograph of the custom-built diffuse optical tomographic breast imaging sys-
tem (DOTBIS). Right: patient placed in the probe for imaging. The patient interface consists of
two sets of four rings that can be adjusted to provide customized setting for different breast cup
sizes.
to visualize the data from all the sources-detectors pairs for each one of the four wavelengths. In
the upper level, we can choose to look at the patient or intralipid raw data, and select dynamic or
static reconstruction mode (2). Static images are reconstructed from patients’s baseline imaging
measurements and the intralipid reference solution imaging. On the other hand, dynamic images
are acquired during increased intrathoracic pressure induced by the breath hold, and 2C)1 data
reconstruction is based on volumetric changes in the concentrations of 2C$21, and 2C1, frame
by frame and relative to baseline concentrations.
Additional elements of the upper panel provide for, among other futures, data filtering (3),
mesh creation (4), source and detector selection or deactivation (5), and forward/inverse file cre-
ation and data reconstruction using a so-called GENeralized Equality Constrained Inverse Solver
(GENECIS) program, which has been developed in our group. In general, this code solves an
optical tomographic problem where the inverse problem is constrained by partial differential equa-
tion (PDE) [151], which uses the diffusion approximation (DA) of the radiative transfer equation
(RTE) to describe the light propagation in such scattering-dominated media as the breast tissue.
Therefore, as illustrated by Figure 2.4, the final tomographic image is generated by minimizing the
mismatch between predictions and measurements of the outgoing light intensities from the tissue
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surface, measured with the optical fibers.
Figure 2.3: MATLAB GUI implemented for data selection automation, filtering and mesh creation.
The windows of the lower panel provide visualization of the patient’s raw data for both breasts.
Each curve in the plot represents the intensity light detected by each detector from source number
1 and wavelength 765 nm for left and right breast.
Given DOTBIS’s wavelength set up (_ = 765, 808, 827 and 905 nm), the spatial distribution of
chromophore concentration of 2C$21, 2C1 and water are available. Additional features such
as total hemoglobin (2C)1) and oxygen saturation ((C$2) were defined respectively as Equation
2.1 and Equation 2.2.





For each of the four wavelengths, changes in the absorption coefficients are calculated at each
node of the mesh determined using our our finite-element reconstruction algorithm. Figure 2.5
shows the display for “Mesh Definition” button. This automated mesh creator allows us to design
personalized meshes (7) according to the ring position set up adapted to patient breast size. In ad-
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Figure 2.4: Model-based iterative image reconstruction diagram: the forward model provides a
prediction of the measurements based on a guess of the system parameters. Then, predicted data
is compared with the measured data, and error is calculated. Finally, if error is still larger than a
threshold, the system parameters of the forward model are updated, which provides a new set of
predicted data. Retrieved and adapted from [152].
ditional, we can also fix the number of elements inside each volume unit (8). Therefore, compared
to the previous protocol adopted by our group, an important criterion added this time is adopting
the same number of elements per unit of volume inside the mesh for all patients. This has critical
impact since absolute concentration reconstructed values depend on the number of mesh elements,
and for fair comparison between different patients, a fix number of elements per volume is essen-
tial. Besides, the old dynamic reconstruction schemes only used two wavelengths, which restricted
the analyses exclusively to ctTHb. Currently, we are using all the 4 wavelengths to also expand our
analyses to water reconstruction values.
Additionally, criteria were establish for patient’s data inclusion. An important start point is
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Figure 2.5: Screen shot of the automated mesh creator implemented in MATLAB for personalized
patient’s mesh. See text for description.
defining what is a so-called valid source-detector pair (SDP). Here we defined a valid SDP, as a
source-detectors pair that has a minimal distance of 2 cm and maximum distance of 9 cm. Fur-
thermore, to be included in the valid SDP set the signal-to-noise ratio (SNR) had to be at least
2dB. To be included in the data analysis, at least 30% of the data collected for a specific patient,
needed to fullfil the threshold minimum criteria of SNR > 2dB. It is important to highlight that
when a SDP was removed from a specific wavelength, it was also removed from the other 3 remain
wavelengths. In this way, it was guaranteed that all SDPs have measurements at all wavelengths.
The impact of bounded boundary values on the reconstructions was also investigated. After
adding a function to set boundary values to background ones, and compare it with standard recon-
struction, the reconstructions were not affected by this type of boundary border, which could be
explained due to the fact that our DCT-based reconstruction [151] is less affected by changes in a
particular node, such as the boundary nodes.
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2.3 Data post-processing and feature extraction
2.3.1 Static features
Static image features are features that are not derived from a series of images that change over
the time of the measurement. For visualizing and extracting static features after reconstruction, I
implemented MATLAB GUI, Figure 2.6. The two windows of the upper panel (middle and right)
provide 3D visualization of selected chromophore concentration for both breasts (9). Besides
3D volume maps, one can also display slices for different x, y and z directions (10) for easy tumor
identification. Tumor volume selection can be done by entering radiologic information (from MRI,
MMG and/or US) such as tumor side, clock position and distance from the nipple (FN) (11).
Figure 2.6: MATLAB GUI implemented for static imaging visualization and feature extraction
after data reconstruction. See text for description.
Regarding tumor-volume selection, I designed an automated code to select the highest value
from the distance FN and the quadrant referent to the clock position entered by the user. For ex-
ample, if the tumor is 2 o’clock and left breast, the automated code will find the highest value from
the upper outer quadrant (from noon to 3 o’clock) as shown in Figure 2.8. Subsequently, a region-
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based image segmentation method is implemented to examine neighboring pixels of the highest
value point detected in the quadrant previously specified. In this way, it is possible to determine
whether the proximate pixel should be added to the region considering a mask of 90%. Another
essential feature was the possibility to exclude the nipple region from post-processing analyses.
This region is highly vascularized and I found that it often degrades the image reconstruction re-
sults. Since not all patients positioned their nipple in the center of the lower ring, I needed to
build a function for manual selection of the nipple central region. After this region is found, a 3D
region growing algorithm for nipple segmentation is applied, Figure 2.7. Finally, I also included
a Maximum Intensity Projection (MIP) subroutine in the visualization aid tool (12). MIP projects
the acquired data volume into a view plane, which can be obtained by finding the voxels with
maximum intensity along a chosen axis [153].
Figure 2.7: Before (top) and after (bottom) using nipple removal function. A) Sagittal MIP image
for right breast of P5 at baseline. B) 3D 2C)1 image for right breast of P5 at baseline.
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After tumor location input and nipple region removal, one saves a final file with the features
extracted for both breasts and for all chromophores. After clicking "Save Excel File", the file
generated includes average and standard deviation for all chromophores in both breasts, including
tumor and non-tumor region.
Figure 2.8: “Clock” positions and quadrants of the breast. Retrieved from NIH SEER Training
Modules https://training.seer.cancer.gov/breast/anatomy/quadrants.html.
In summary, static features include average concentration values of 2C$21, 2C1, 2C)1,
(C$2 and F0C4A for three regions of interest: tumor volume, non-tumor volume from the affected
breast, and contralateral breast.
2.3.2 Dynamic features
Unlike static feature, dynamic feature are extracted from a series of images taken over the time
of the measurement (about 2-4 minutes). Figure 2.9 shows the main tools that were implemented
for the task of extracting these feature from the raw data. Both windows of the lower panel (middle
and right) provide 3D visualization of the distribution of 2C)1 relative to baseline concentrations
at a specific frame during breath hold for both breasts (13). Additional tools allow the user to chose
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between 3D map or MIP image display (14), record the 2C)1 average changes across time (15),
and show a particular slice in any x, y and z directions for easy tumor localization (16). Figure
2.10 displays the cross-sectional images of the 3D 2C)1 maps at different time points over the
course of a breath hold. Tumor selection is performed using the same methodology for static
feature extraction (17). After the tumor is located, the user can visualize hemodynamic curves for
3 regions of interest: tumor volume, tumor-bearing breast, and contralateral non-tumor-bearing
breast.
Figure 2.9: MATLAB GUI implemented for dynamic imaging visualization and feature extraction
after data reconstruction. Lower left panel shows the hemodynamic curves for 3 regions of interest:
tumor volume, the entire tumor-bearing breast, and the contralateral non-tumor bearing breast.
Also included are their respective key point selection for feature extraction. The black arrows
point to the tumor region selection.
From the quantification analysis of the hemodynamic traces, which can be divided into breath
hold and recovery (after patient resume normal breathing), Figure 2.11, we determine the flow-
in slope (g8=), wash-out slope (g>DC), and the ratio between the maximum signal intensity and the
time-to-peak (MITR). These features characterize the shape and structure of the 2C)1 time-trace.
Notably, the hemodynamic response function usually exhibit a sigmoid time dependence. A
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Figure 2.10: 65 y/o patient with a tumor at 2 o’clock in the right breast. Image shows a cross
section view at 4 cm from nipple in 8 different time points during a breath hold. Tumor region is
indicated by the black dashed line.
sigmoid model predicts that initial behaviour proceeds exponentially, then slows and eventually
saturates to produce the characteristic S-curve [154]. Therefore, a second quantification analysis
approach fits the 2C)1 time-trace to a variation of the Hill equation defined by the three-parameter
sigmoid function Equation 2.3. )1
2
denotes the point of inflection in the response curve at which
mean 2C)1 is 50% of the maximal mean 2C)1 level (2C)1"-), and d is the slope at the
steepest part of the curve. Since the 2C)1 trace is defined by two curves, breath hold and recov-









In addition, I also developed a method to quantify the areas that are high in signal intensity at
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Figure 2.11: An example of 2C)1 time-trace from the tumor volume showing the different met-
rics that characterize hemodynamic changes in the breast tumor during a breath hold.
the end of breath hold (i.e. 2C)1"-) compared to 50% of the maximum value at the end of
breath hold (2C)1"-50%). This allows for a comparison the effect of enhanced 2C)1 values
estimated from an early versus after breath hold measurement, Figure 2.12. In our fully-automated
algorithm, the 2C)1 enhanced ratio was estimated by evaluating the difference of each voxel’s
2C)1 value in the 3D breast volume image at the end of the breath hold (i.e. 2C)1"-) relative
to 2C)1 value in the corresponding 2C)1"-50% volumetric image. This voxel-wise enhance-







A new dynamic feature named as DOT-THbE was defined as the total volume (2<3) of en-
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Figure 2.12: Quantification of the 2C)1 enhanced ratio at the end of the breath hold (i.e. In
this example, we have the 2C)1 time trace for all the 3 region of interest: tumor volume (red),
breast bearing the tumor (blue) and the contralateral breast (green). 2C)1"- was registered at
frame 45 and 2C)1"-50% at frame 18. Correspondent images are presented in MIP and 3D map
distribution visualization. Tumor region is indicated by the black dashed line.
hancing voxels whose 2C)1 enhanciment ratio (i.e. '%) had a value equal to or greater than an
enhancement ratio threshold ('%2DC−> 5 5 ), Equation 2.5. Next, we estimated the total volume of
DOT-THbE in a percentage-based notation as defined by Equation 2.6, where V refers to the total
volume breast (2<3).




'% ≥ '%2DC−> 5 5
)
(2.5)







2.4 Validation of the reconstruction methodology
The reconstruction’s results were compared to an open source software for multi-modal optical
molecular imaging, NIRFAST [155]. This work was important for validating our data reconstruc-
tion methodology to a well-established image reconstruction package. The comparison between
both reconstruction methods is shown in Figure 2.13. The similarities between both results are
clearly noticeable, even though there is a different in the absolute values. Absolute values are
different becauset the breast parameter values adopted for GENECIS and NIRFAST are different
as well. But, the overall chromophore concentration distribution and changes across time (for
dynamic feature extraction) are quite similar.
Figure 2.13: Comparison between GENECIS (bottom) and NIRFAST (top) dynamic results for
P2. A) Plot of ctTHb average percentage changes during a breath hold window for both breasts.
B) Sagittal MIP image for left and right breasts. C) Images of cross sections at 6.5 cm from the
nipple; the black arrows appoint to the expected tumor region location, which correlates with high
ctTHb concentration values.
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2.5 Patient and Clinical characteristics
For this study 105 breast cancer patients were enrolled. Seventeen patients were subsequently
excluded from the final analysis. The reasons for exclusion included patient withdrawal (n=4),
missing baseline DOTBIS measurement due to instrumentation failure (n=8), patient under inves-
tigational and none-FDA approved drug regimen (n=1), and machine operator error (n=4). One
patient had bilateral breast cancer, and both tumors were added to the analysis. Therefore, the re-
sults reported here include 88 patients and 89 tumors in total. RCB scores were not available for 6
cases, including the two cases with tumors in boths breasts. Not all the patients had their DOTBIS
reconstruction available for all of their imaging time points because some patient declined imaging
at that particular DOTBIS time point or machine malfunction.
Overall, 82 (93%) patients had DOTBIS images successfully reconstructed at baseline (TP0),
70 (80%) patients at 2-3 weeks from taxane initiation (TP1) and 52 (59%) at pre-surgical time
point (TP5). In total, 36 did not have TP5 imaging available. The reasons for missing data were:
patient declined to be imaged (19/36); machine operator did not collect/save the data correctly
(5/36); data not collected due to machine under repair (12/36). Out of the 58 patients who were
under T x 12/AC x 4 regimen (n = 54) or T/C x 12/AC x 4 (n = 4), 46 (79%) had their data acquired
and reconstructed at TP2, 43 (74%) at TP3 and 40 (69%) at TP4. Other regimens accounted for
the remaining 30 patients. Twenty-two patients (25%) with HER2+ breast cancer received six
cycles of docetaxel, carboplatin, and trastuzumab plus pertuzumab (TCHP). Six patients (6.8%)
received six cycles of cytoxan plus taxotere (T/C x 6) and 1 patient (1.1%) received just four cycles
of cytoxan plus taxotere (T/C x 4). Lastly, one patient (1.1%) received paclitaxel, trastuzumab,
and pertuzumab followed by doxorubicin and cyclophosphamide (THP/AC). Patient, clinical and
tumor characteristics are summarized in Table 2.1 and Table 2.2. Patient data is also individually
presented in Appendix A.
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Age (mean ± SD) BMI (mean ± SD)
Chemotherapy and targeted therapies
T x 12/AC x 4 54 48.48 ± 11.52 29.89 ± 7.18
TCHP 22 54.00 ± 9.83 29.36 ± 9.35
T/C x 6 6 59.67 ± 12.24 30.54 ± 3.24
T/C x 12/AC x 4 4 39.25 ± 8.65 30.05 ± 2.29
T/C x 4 1 30 18.11
THP/AC 1 40 32.23
Menopausal status
Premenopausal 52 41.65 ± 6.90 29.48 ± 7.91
Postmenopausal 35 61.63 ± 6.00 30.10 ± 6.82
Uncertain 1 56 27.16
Table 2.2: Tumor characteristics for all the 89 tumors considered for analysis.














Chapter 3: NAC monitoring with Static DOTBIS - Tumor Volume
3.1 Introduction
The purpose of this study is to investigate if changes in the tumor bearing breast in response to
NAC, as assessed with static DOTBIS, can be used to predict treatment outcome. In particular, we
are focusing in this chapter on quantitative measurements of tissue functional components, such as
total hemoglobin concentration (2C)1) and water percentage (F0C4A) in the tumor. We hypoth-
esize that 2C)1 and F0C4A changes after 2-3 weeks of chemotherapy initiation are associated
with pCR and are dependent on breast carcinoma subtype. In the case of more than two measure-
ments per subject, classical statistical procedures are available, and the analysis of longitudinal
data is reduced to the analysis of independent observations. Simple to interpret, the results will
show analysis of the data at each imaging time session separately, and assess the differences on the
earliest time point (TP1). However, these two methods have the disadvantage of not allowing to
analyze how much subjects tend to change overtime, highly correlated measurements on the same
subject, and possible problems with missing data. Therefore, to be able to distinguish differences
between subjects from changes within subjects, and minimize the missing data points, we have
also added longitudinal data analysis based on a multilevel mixed-effects model.
3.2 Results - Part I: Analysis at each time point separately
A total of 36 tumors (40%) achieved pCR, while 53 (60%) were classified as non-pCR, i.e.
RCB > 0. Figure 3.1 provides the sagittal MIP of the reconstructed 3D 2C)1 map within the
breast bearing the tumor of two 46 years old women, one pCR and another one non-pCR, re-
spectively. Mean concentration values for each chromophore acquired from the tumor region were
normalized by the mean values calculated from the non-tumor volume, and they express the magni-
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tude of tumor concentration values in respect to the non-affected tissue, Equation 3.1. For notation
purposes, the normalized feature is identified by the subscript letter N, i.e.: 2C1# . In addition,
the normalized features for each imaging time point acquired after NAC initialization were stan-
dardized by the normalized values acquired at baseline (TP0), Equation 3.2. This proposed ratio
directly evaluates the percentage change in relation to the baseline values and are represented by
the symbol Δ . For instance, to represent the difference between the 2C1# measured at TP1









After NAC completion, pCR tumors had lower 2C)1# (2.09 ± 0.97) compared to 2C)1#
values at baseline (3.69 ± 2.29), p = .009, an overall decrease of 1.59 (95% CI, 0.45 to 2.73) in
2C)1# levels. In contrast, non-pCR tumors had a statically significant increase of 1.22 (95%
CI, 0.24 to 2.19) in the 2C)1# levels after NAC treatment completion (4.21 ± 2.86) compared
to 2C)1# baseline values (2.99 ± 2.02), p = .016. 2C)1# levels were also statically significant
lower for pCR group (2.62 ± 1.36), p = .043, and higher for non-pCR (5.56 ± 4.75), p = .005, at
the end of NAC regimen. At the earliest imaging point after starting therapy, TP1, the pCR group
had an overall reduction of 1.94 (95% CI, 0.42 to 3.47), p = .015, in 2C)1# levels, while the
non-pCR group increased by 0.76 (95% CI, 0.36 to 1.16), p < .0005. After running an independent
t-test, Δ)%12C1# was statistically significantly higher in non-pCR (1.28 ± 0.53) than in pCR
(0.78 ± 0.29) patients, p < .0005. Significant differences were also reported for Δ)%12C)1# , p
= .028 and Δ)%1(C$2# , p = .050, at TP1. Δ)%22C)1# and Δ)%22C1# were also statistically
significantly different between pCR and non-pCR groups as show in details in Figure 3.2.
A Pearson’s product-moment correlation was run to assess the relationship betweenΔ)%12C1#
and RCB scores. There was a statistically significant moderate positive correlation between changes
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Figure 3.1: Sagittal MIP of the reconstructed 3D 2C)1 map within the breast bearing the tumor
of (A) a 46-year-old woman who achieved pCR after NAC for HER2+ breast cancer, and (B) a
46-year-old woman and HER2- breast cancer who was classified as RCB III (non-pCR). NAC
drug regimen protocol includes 12 cycles of weekly paclitaxel (blue) followed by 4 cycles of
AC given every 2 weeks (yellow). DOTBIS images corresponding to baseline, before the first
taxane treatment (T1), before her third and fifth taxane cycle (T3, T5), before her first and second
AC cycles (AC1, AC2), and pre-surgery (PS) were arranged from left to right. Nipple region is
identified by the dashed circle line.
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in 2C1# after 2-3 weeks of NAC and RCB score after chemotherapy, A (66) = .448, p < .0005.
Data are mean ± standard deviation.
Figure 3.2: Mean ratio (+ 95% CI) of 2C)1# , 2C$21# 2C1# , (C$2# and F0C4A# compared
to reference (baseline) values measured at TP0 for each one of the 5 imaging time points after
starting NAC regimen for pCR and non-pCR groups. Early changes were statistically significant
different between both groups at TP1 for Δ2C)1# , Δ2C1# and Δ(C$2# . Only independent
t-tests with a statistical significance at p <.05 level were reported. The dashed line and black arrow
indicate ratio equal to 1.0. Mean ratio values below the line indicates a reduction in the normalized
values compared to baseline. One can notice that non-pCR group follow a trend of increase in
Δ2C)1# and Δ2C1# over time while pCR group stays below the no change threshold (i.e.
ratio = 1.0). Numbers inside bars indicate sample size.
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3.2.1 HR+/HER2- subgroup
A total of 11 (24%) of the 45 patients with a HR+/HER2- tumor achieved a pCR. Results of
the paired-samples t-test for pCR group show that mean 2C)1# statistically differs at baseline
(2.92 ± 1.09) and after NAC (1.64 ± 0.78), p =.005. On average 2C)1# was about 1.29 lower
after receiving NAC (TP5). 2C$21# 1.09 (95% CI, 0.47 to 1.72), p =.008, and 2C1# 1.43
(95% CI, 0.14 to 2.84), p =.049, levels were also statically significant reduced at NAC treatment
completion. On the other hand, the non-pCR group shows a statistically significant increase of 1.58
(95% CI, 0.26 to 2.89), p = .021, in 2C1# levels after NAC treatment completion. 2C1# ,
2.10 (95% CI, 0.59 to 3.61), p =.009, and F0C4A# , 9.1% (95% CI, 3.9 to 17.20), p =.029, levels
were also statically significant higher for non-pCR at TP5. An independent-samples t-test was run
to determine if there were early differences in the ratio of normalized features measured at TP1
and compared to baseline between the pCR and non-pCR groups. Δ)%12C1# was lower to pCR
(0.87 ± 0.33) than non-pCR (1.23 ± 0.34), a statistically significant difference of 0.37 (95% CI,
0.08 to 0.66), p = .014, Figure 3.3 (A).
3.2.2 HER2+ subgroup
Out of the 27 patients with a HER2+ tumor, 17 (63%) achieved pCR. NAC was associated with
a decrease in 2C1# levels for pCR group 3.49 (95% CI, -0.88 to 7.86), p =.104, and an increase
for non-pCR 3.33 (95% CI, -3.11 to 9.77), p =.253, but this mean differences at the end of NAC
(TP5) compared to baseline were not statistically significant. However, there was a statistically
significant mean decrease in 2C1# levels 2.64 (95% CI, 0.92 to 5.18), p =.043, after only 2-
3 weeks of therapy (3.40 ± 1.79) compared to baseline values (6.04 ± 5.51), whereas, patients
without a pCR had a non-statistically mean increase of 1.37 (95% CI, -0.43 to 3.17), p =.117, at
TP1 (3.72 ± 2.62) compared to TP0 (2.35 ± 0.54). At TP1, patients with HER2+ tumors that had
complete response to NAC, had lower mean Δ)%12C1# levels (0.74 ± 0.30) than non-pCR (1.54
± 0.98), p = .041. Statistically significant differences between those with and without a pCR in the
HER2+ cohort were also reported for Δ)%22C1# , p = .023, Figure 3.3 (B).
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3.2.3 TNBC subgroup
Nine TNBC patients exhibited pCR. Results of the paired-samples t-test show that mean 2C)1#
in pCR tumors differs at baseline (2.97 ± 0.88) and after NAC (1.81 ± 0.50), but not at the .05 level
of significance (p=.243). However, patients with a pCR had a statistically significant mean de-
crease in 2C)1# levels 1.54 (95% CI, 0.62 to 2.46), p =.010, after one-month (TP2) of therapy
(2.29 ± 0.55) compared to baseline (TP0) values (3.83 ± 0.50). An independent-samples t-test was
run to determine if there were differences in the ratio of each normalized feature compared to base-
line between pCR and non-pCR tumors. At TP2, after one month since chemotherapy initiation,
patients with a TNBC tumor who achieved a pCR to NAC had lower mean Δ)%22C)1# levels
(0.61 ± 0.16) than those without a pCR (1.68 ± 0.98), p = .044, Figure 3.3 (C). No statistically
significant difference was reported for any additional feature at any other different time point.
3.3 Results - Part II: Analysis of earliest endpoint (TP1)
To test the relationship between the likelihood that a tumor will not achieve pCR after NAC,
a logistic regression model was employed by using the changes in normalized optical features
measured at TP1 and combined to tumor phenotype. Separately, HER2 status, Δ)%12C1# ,
Δ)%1(C$2# and Δ)%12C)1# were significant related to pCR status. However, when all predictor
variables are considered together, only HER2 status and Δ)%12C1# were significant predictors
of whether a patient will achieve a pCR. This suggests some association among the other predictors,
Δ)%1(C$2# and Δ)%12C)1# . Therefore, Δ)%12C1# combined with HER2 status were used
as a two-predictor logistic model. The logistic regression model was statistically significant, j2(2)
= 35.510, p < .0005. The model explained 55.1% (Nagelkerke '2) of the variance in pCR status
and correctly classified 75.4% of cases. According to the model, the log of the odds of a patient not
responding to NAC was positively related to Δ)%12C1# (p =.001) and related to HER2 status (p
=.024). In other words, the higher the Δ)%12C1# ratio, the less likely it is that the patient will
have a pCR. Given the same Δ)%12C1# value, patients with HER2+ breast cancers were 4.8
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Figure 3.3: Early changes in 2C1# were statistically significant different between pCR and non-
pCR groups at TP1 for HR+/HER2- (A) and HER2+ subgroups (B). For patients with TNBC (C),
response prediction appears to be best at the completion of the first four cycles of NAC (TP2). Only
independent t-tests with a statistical significance at p <.05 level were reported. The dashed line and
black arrow indicate ratio equal to 1.0. Mean ratio values below the line indicates a reduction in
the normalized values compared to baseline. Numbers inside bars indicate sample size.
times more likely to have a pCR than those with HER2- tumors. Receiver-operating characteristics
(ROC) of the proposed logistic regression model indicated an excellent level of discrimination
employing the criteria defined by Hosmer et al [12]. Sensitivity was 95.5%, specificity was 64.0%,
with a positive predict value of 81.8% and a negative predict value of 64.0%. The area under the
curve (AUC) was .891, p < .0005, with 95% confidence interval (.812, .969).
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3.4 Results - Part III: Longitudinal multilevel mixed-effects model
Statistical models can incorporate both fixed and random effects. Fixed effects are terms rep-
resenting the average trajectory, and they are associated with an entire population. Random effects
reflect deviation from the average trajectory for each individual, and the effects that arise from
uncontrollable variability within the sample. Therefore, a model with both fixed and random ef-
fects is called a mixed-effect model, which systematically account for within subjects variability
and within group variability. One of the main applications of mixed-effects models is to describe
relationships between a response variable and some covariates in data that are grouped according
to different classification factors [156]. Examples of such grouped data include longitudinal data,
which occur when a series of measurements are made on each individual in the sample, over some
period of time.
Given the study design, optical based features (i.e. 2C$21, 2C1, 2C)1, (C$2 and F0C4A)
were measured multiple times on the same patient - three times, Figure 3.4, or six times, Figure
3.5, depending on patient’s regimen - and these features were acquired from patients organized in
different levels (e.g. pCR classification, molecular subtype or menopausal status).
As illustrated by Figure 3.4 and Figure 3.5, time varying predictors appears at level 1, since
they are associated with specific multiple measurements. A predictor is time varying when it is
measured at multiple points in time, just as is the outcome variable. On the other hand, time invari-
ant predictors will appear at level 2, since they are related to the subject across all measurement
condition. A predictor is time invariant when it is measured at only one point in time, and its value
does not change across measurement occasions [157]. This longitudinal two-level mixed-effects
model design will allow us to investigate and answer the main questions below:
1. How 2C1# evolves overtime for this cohort of patients?
2. Does pCR group classification change average longitudinal evolution?
3. Do pCR tumors have lower 2C1# levels during follow-up compared to non-pCR?
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4. Is there a difference in the average longitudinal evolution of 2C1# when we correct for
pCR group classification (or molecular subtype and menopausal status)?
Figure 3.4: Two-level model where we have repeated measures on individuals imaged three times:
baseline (TP0), 2-3 weeks after the first taxane infusion (TP1) and pre-surgery (TP5), and in dif-
ferent treatment response classification (pCR versus non-pCR group). In total, 34 patients were
imaged three times, and 17 were pCR and 17 non-pCR.
3.4.1 Longitudinal analysis: Three time-point imaging study
Fitting longitudinal models in a multilevel framework can be done by using two primary pack-
ages in R for mixed models analysis: nlme or lme4. The multi-level modeling package we will
use for all analyses in this study is the nlme package. This package allows for both random effects
and correlated error terms, it fits linear and nonlinear mixed effects models, and has several options
for covariances matrices and variance functions [158]. The function to fit linear mixed models in
the nlme package is lme(), and has three essential arguments:
• fixed: formula specifying the response vector and the fixed-effects structure.
• random: formula specifying the random-effects structure.
• data: data frame containing all the variables.
In order to apply multilevel modeling techniques to longitudinal analyses, the data frame that
contains all variables should be in the long format. In this format, rather than having one row for
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Figure 3.5: Two-level model where we have repeated measures on individuals imaged six times:
baseline (TP0), 2 weeks after the first taxane infusion (TP1), after 4 infusions of taxane (TP2), at
the end of the taxane regimen and before starting AC cycle (TP3), after two AC infusions (TP4)
and pre-surgery (TP5), and in different treatment response classification (pCR versus non-pCR
group). In total, 55 patients were imaged three times, and 20 were pCR and 35 non-pCR.
each patient, a single row is used for each time that each patient is measured. Therefore, the data
frame will consist of as many rows as there were measurements made. For this three time points
analysis, 34 tumors were included, 17 pCR and 17 non-pCR. All the individuals did not have im-
age data available at all time points. But, since we are using multi-level modeling, it was possible
to account for all the individuals. Even if a patient has imaging available from only one session,
she can still be added to the model. Other methods such as repeated measures ANOVA, same ap-
proach would be not possible since you require all cases to be completed, and consequently large
amount of information would be lost. For the construction of this model, HHb_N was defined as the
outcome/dependent variable, Days_of_NAC as the repeated measure, and PCR_bin, molec-
ularSubtype and MenopausalStatus as predictors/independent variables. Study records
were organized in a long-format spreadsheet, TP3_Long.xlsx, which included the following
variables:
• Patient_Number: patient ID number
• Days_of_NAC: time under NAC therapy
(0 = baseline, 1 = after 2 or 3 weeks, 5 = pre-surgery)
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• PCR_bin: tumor response classification
(1 = pCR, 2 = non-pCR)
• molecularSubtype: molecular tumor subtype
(1 = TNBC, 2 = HER2+, 3 = HR+/HER2-)
• MenopausalStatus: patient menopausal status
(1 = pre, 2 = post)
• HHb_N: time measured 2C1#
It is important to highlight that time points should be rescaled such that the first time point is
0. So, technically, imaging session number one (TP0), imaging session number two (TP1) and the
last imaging session (TP5) are labeled 0, 1 and 5. By starting with zero, we can set a baseline for
the intercept, which can be interpreted as the predicted outcome for baseline or time 0. Also, in
order to investigate whether we can differ the 2C1# means at specific time point, we will need
to redefine Days_of_NAC as categorical covariates.
#STEP 1: Upload dataset
library("readxl")
Data1 <- read_excel("TP3_Long.xlsx", sheet=1)
Data1$Days_of_NAC <- factor(x = Data1$Days_of_NAC,
labels = c("TP0", "TP1", "TP5"))
After uploading the data set in long format, we can start building our model with the uncondi-
tional means model (mod1), which is the null model to test the null hypothesis that the intercept
is significantly different from zero. At this point, we are evaluating how much the grand mean (or
intercept) differs from zero at baseline, and we can reject the null model that you do not have any-
thing to measure within the model itself. Next step is to add the dependent variable into the model,
HHb_N. From the study design, we know that HHb_N is available for multiple imaging session.
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Therefore, it is of great interest to have the patient time sets compared to one another, and the indi-
viduals nested within themselves. However, be aware that, at this stage, we do not have any slope,
and we do not have any real random effects either. We are only measuring the grand mean, time
is not being measured within this model, and there is no predictors (independent variables). For
this method, we will use maximum likelihood (ML), which includes both regression coefficients
(fixed-effects) and the variance components (random-effects) terms in the likelihood function.
#STEP 2: Open "nlme" package
library(nlme)
#STEP 3: Unconditional Model
mod1 <- lme(HHb_N~1, random=~1|Patient_Number, data=Data1,
method = "ML", control=lmeControl(opt='optim'),
na.action=na.exclude)
The function summary() can be used to report the logLik value. The logLik value for
this model was -218.2567. Ideally, this number should decrease each time a new variable is
added to the model as an indication that we are improving the overall fit of our model. As we start
building upon our model, we can use logLik to compare the models between themselves, and
evaluate how much the new proposed model is improving performance. As we moved to the next
stages, and design the unconditional growth model to better fit the data, we expect that logLik
value will decrease, and then we can test whether this change is significantly different from the
original model.
Random effects values give the standard deviation for both intercept and residual. From
these values we can calculate the intraclass correlation coefficient (ICC) define by Equation 3.3:
(variance of interest)




The ICC value quantifies the clustering that could potentially exist within the data, and it provides
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a reasonable justification for a multi-level analysis approach. Any value below 0.05 would suggest
that clustering is not taking place. A large ICC indicates there is potential clustering taking place,
and multi-level modeling on the data is recomended. The result is .20, which implies a considerable
amount of clustering taking place, and as a next step, we will need to select a proper slope and
predictors to see how much of that variability we can account for.
Then, moving to the Fixed effects output, where we evaluate 2C1# with no slope, the
p-value is significant. This means that for 2C1# , the grand mean or intercept is 4.7805 and
significantly differs from zero. The last output shows the total Number of Groups:34, which
means there were 34 individuals that took part in the three time-point study, and the observations
differ. On the other hand, the Number of Observations:77 means that some individuals
did one imaging session, some did two imaging sessions, and some did all the 3 imaging sessions,
and that summarizes the total number of measurements taken from all patients under the three
time-point study.
summary(mod1)
## Linear mixed-effects model fit by maximum likelihood
## Data: Data1
## AIC BIC logLik
## 442.5134 449.5448 -218.2567
##
## Random effects:
## Formula: ~1 | Patient_Number
## (Intercept) Residual
## StdDev: 1.881337 3.729953
##
## Fixed effects: HHb_N ~ 1
## Value Std.Error DF t-value p-value
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## (Intercept) 4.780489 0.5427983 43 8.807118 0
##
## Standardized Within-Group Residuals:
## Min Q1 Med Q3 Max
## -1.60263436 -0.44660399 -0.28377845 0.07268916 4.19009931
##
## Number of Observations: 77
## Number of Groups: 34
In summary, by running the unconditional means model (mod1), we were able to reject the
null model that the grand mean does not differ from zero. Hence, we can proceed to add a slope
to the data by designing an unconditional growth model. There are two different types of slope:
the fixed slope (mod2) and the random slope (mod3). The fixed slope assumes that all patients
within the data is following a similar pattern over time (increasing or decreasing). Whereas a
random slope allows individual variability, meaning patients might have unique traits amongst
themselves, and their levels of progression might vary widely. In the first model (mod1), the
only variable included was 2C1# . For the unconditional growth model, we will also include
a time variable, Days_of_NAC, which will help us to set the slope for our study by testing out
whether Days_of_NAC is best represented as having a fixed or a random slope. For (mod2),
we are going to treat Days_of_NAC with a fixed slope, which means that all patients should be
progressing in the same direction.




From summary(mod2), we can check logLik value, which is still almost identical to
(mod1). Equation 3.4 gives the ICC for the new model. The value is similar to the previous
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model (mod1). Ideally, if a large amount of the clustering is accounted by the slope, the ICC
should decrease over time. In (mod2), Days_of_NAC is fixed across individuals, if we look
at the results from the Fixed effects output, p-value it is not significant. When running the
function intervals(mod2), we can observe that time as a fixed slope is not significant (95%
confidence interval does include zero). Therefore, designing a fixed slope for the individuals is
not capturing the fit of the model. But, if we look at the results from the Random effects,
these are significant (95% confidence interval does not include zero), meaning there is still a lot of
variability that needs to be accounted for within the model. That is promising because indicates
that there are other ways to better structure this model, such as setting the slop as a random effect.
summary(mod2)
## Linear mixed-effects model fit by maximum likelihood
## Data: Data1
## AIC BIC logLik
## 445.7007 457.4198 -217.8504
##
## Random effects:
## Formula: ~1 | Patient_Number
## (Intercept) Residual
## StdDev: 1.901139 3.699215
##
## Fixed effects: HHb_N ~ Days_of_NAC
## Value Std.Error DF t-value p-value
## (Intercept) 4.488762 0.7487277 41 5.995186 0.0000
## Days_of_NACTP1 0.199272 1.0004864 41 0.199175 0.8431





## Days_of_NACTP5 -0.525 0.393
##
## Standardized Within-Group Residuals:
## Min Q1 Med Q3 Max
## -1.5298242 -0.4480429 -0.2660336 0.1659026 4.3038491
##
## Number of Observations: 77






## Approximate 95% confidence intervals
##
## Fixed effects:
## lower est. upper
## (Intercept) 3.006424 4.4887619 5.971099
## Days_of_NACTP1 -1.781500 0.1992715 2.180043
## Days_of_NACTP5 -1.265772 0.9985962 3.262964
## attr(,"label")





## lower est. upper
## sd((Intercept)) 0.8938364 1.901139 4.043613
##
## Within-group standard error:
## lower est. upper
## 2.990447 3.699215 4.575967
In (mod3), Days_of_NAC is accounted as a random slope, which takes in consideration in-
dividual variability. For the new model (mod3), whereas (random = ∼1|Patient_Number)
was adopted for (mod2), now it is fixed as (random = ∼Days_of_NAC|Patient_Number).
Having this new set up, we can account for individual variability, meaning 2C1# levels for some
individuals may go up, and for other ones might go down based on their Days_of_NAC.




After running summary (mod3), the logLik value is -213.3631, which shows a better
fit towards the data. In addition, when we look at the Fixed effects output, Days_of_NAC
is not significant because for the sole purpose that it is not a fixed effect. Also, by adding a random
slope, the new model has an ICC of 0.44, Equation 3.5, which means clustering is higher, and there
is more variability being accounted for within the data set.
summary(mod3)
## Linear mixed-effects model fit by maximum likelihood
## Data: Data1
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## AIC BIC logLik
## 425.8709 449.3089 -202.9354
##
## Random effects:
## Formula: ~Days_of_NAC | Patient_Number
## Structure: General positive-definite, Log-Cholesky parametrization
## StdDev Corr
## (Intercept) 3.9278481 (Intr) D__NAC
## Days_of_NACTP1 4.5600048 -0.660
## Days_of_NACTP5 6.4329723 -0.538 0.977
## Residual 0.8137187
##
## Fixed effects: HHb_N ~ Days_of_NAC
## Value Std.Error DF t-value p-value
## (Intercept) 4.532876 0.7202890 41 6.293135 0.0000
## Days_of_NACTP1 0.440189 0.8659426 41 0.508335 0.6139




## Days_of_NACTP5 -0.523 0.913
##
## Standardized Within-Group Residuals:
## Min Q1 Med Q3 Max
## -1.15674487 -0.13372030 -0.04366578 0.17481609 1.32791732
##
## Number of Observations: 77
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Lastly, by running deviance statistics (ANOVA test) we can compare the three models across
one another to see how much adding each predictor to the model increases the overall fit of the
model. For anova(mod1,mod2), p-value = .3673 is not significant, and we can conclude that
by including a slope that is fixed across Days_of_NAC does not captures the fit of the data. On
the other hand, for anova(mod1,mod3), p-value < .0005 is statistically significant, and we can
infer that is a better fit towards the data.
# STEP 6: Run deviance statistics
# Compare mod1 to unconditional growth model-fixed slope (mod2)
(results <- anova(mod1,mod2))
## Model df AIC BIC logLik Test L.Ratio p-value
## mod1 1 3 442.5134 449.5448 -218.2567
## mod2 2 5 445.7007 457.4198 -217.8504 1 vs 2 0.8126817 0.6661
# Compare mod1 to unconditional growth model-random slope (mod3)
(results <- anova(mod1,mod3))
## Model df AIC BIC logLik Test L.Ratio p-value
## mod1 1 3 442.5134 449.5448 -218.2567
## mod3 2 10 425.8709 449.3089 -202.9354 1 vs 2 30.64255 1e-04
Up to this point, we have set up the intercept and the grand mean, the proper slope that better
fit the model, and established the repeated measures to compare amongst 2C1# levels. As
last step, we will design the full model, or the conditional growth model, which includes all the
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predictors from the research question to evaluate whether these predictors would have a role in
modeling 2C1# levels over time.
The new full model, (mod4), has 2C1# as dependent variable, Days_of_NAC as a ran-
dom effect and random slope across individuals, and PCR_bin, molecularSubtype and
MenopausalStatus as predictors in the model. Please note that we are particularly inter-
ested in the group-occation interaction (Days_of_NAC∗PCR_bin) as this reflects a potential
difference in time evolution between the groups. Due to space constraint, summary() results for
(mod4) can be find in Appendix B.
# STEP 7: Conditional growth model




The summary() results, return a logLik value even lower then the one from the last model,
(mod3). From the fixed effects output, we observe a significant decrease in mean 2C1# from
baseline to TP1, p =.0174, and also a significant decrease from baseline to TP5, p =.0127. The
interaction between Days_of_NAC with PCR_bin describes the difference in changes since
baseline between the pCR and the non-pCR group (the differences of the differences), and it is
significant at both TP1, p =.0082 and TP5, p =.0026. This indicates that the mean 2C1# over
time differ significantly between pCR and non-pCR groups. This trend can be also observed in the
iteration plot of 2C1# levels over the different time points for both pCR and non-pCR groups,
Figure 3.6. As appears mean 2C1# is different between molecular subtypes groups at baseline,
p =.0413, but not across time, Figure 3.7. No significant differences were found between pre- and
post-menopausal groups, Figure 3.8.
Next, we will compare the deviance statistics to evaluate the full model (mod4) performance
in terms of fit compared to last model (mod3). From the result, the difference is significant, p
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Figure 3.6: Top: Plot to illustrate the interaction between the mean response for two-way com-
bination of factors: Days_of_NAC and PCR_bin over 3 time points. Bottom: Box plots and
95% confidence intervals for 2C1# in the three time point study separated by tumor response
to NAC: pCR (Left) non-pCR (Right) groups.
=.0214, so we can conclude the predictors we have included within model (mod4) are predicting
2C1# within the data, and accounting for the correlation in the data as well as possible changes
in variances/standard deviations over time.
# Compare (mod3) to the full conditional growth model (mod4)
(results <- anova(mod3,mod4))
## Model df AIC BIC logLik Test L.Ratio p-value
## mod3 1 10 425.8709 449.3089 -202.9354
## mod4 2 15 422.6504 457.8075 -196.3252 1 vs 2 13.22048 0.0214
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Figure 3.7: 2C1# versus time (3 time points) by pCR group (pCR and non-pCR) for pre- and
post-menopausal groups. Smooth curve plot was computed by least-squares fitting.
To provide the unexplained variance captured in the full model, we calculate the proportion
reduction between (mod3) and (mod4) at level 2 considering all the predictors. Moving from
(mod3) to (mod4), we can quantify the proportion reduction taking place after adding the pre-
dictors within the model, and the full model, (mod4), accounts for 30% of the unexplained vari-
ance.
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Figure 3.8: 2C1# versus time (3 time points) by pCR group (pCR and non-pCR) for each
molecular subtype breast cancer group (TNBC, HER2+ and HR+/HER2-). Smooth curve plot was
computed by least-squares fitting.









3.4.2 Longitudinal analysis: Six time-point imaging study
For the six time-points longitudinal study, 55 breast cancer tumors were included, 20 had pCR
and 35 were classified as non-pCR. In order to evaluate whether pCR status, menopausal status
and molecular subtype classification influence the change of 2C1# over time for patients un-
der the six time-point imaging study, we designed a multilevel mixed-effect model. Using same
methodological approach for the model presented in the three time-point imaging study, 2C1#
was defined as dependent variable, Days_of_NAC as a random effect, and PCR_bin, molec-
ularSubtype and MenopausalStatus as predictors in the model. Please note that we are
particularly interested in the group-occation interaction (Days_of_NAC∗PCR_bin) as this re-
flects a potential difference in time evolution between the pCR groups. From the plot interaction
output, Figure 3.9, we can observe different trends in the changes of 2C1# over time for the
two pCR groups (pCR versus non-pCR). On the other hand, dramatic differences are not observed
according to menopausal status, Figure 3.10, or molecular subtype classification, Figure 3.11.
From the summary() output, added in Appendix B due to space constraint, the estimate av-
erage 2C1# for pCR tumors at baseline is 4.02. For the next time point, TP1, 2C1# is
estimated to decrease on average -1.31, p =.0005 for pCR group. The change from TP1 to TP2 is
also statistically different, p = .0145, but not for the remaining time points. Non-pCR group had
statistically siginificant increase in 2C1# levels after all time points except TP3. These results,
we see that, again, time is related to changes in 2C1# , and there are differences in time evo-
lution between the pCR groups. Thus, we can conclude that changes is 2C1# levels over the
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Figure 3.9: Top: Plot to illustrate the interaction between the mean response for two-way combina-
tion of factors: Days_of_NAC and PCR_bin over 6 imaging time points. Bottom: Box plots and
95% confidence intervals for 2C1# in the three time point study separated by tumor response
to NAC: pCR (Left) non-pCR (Right) groups.
six imaging time points do differ from pCR to non-pCR tumors. No significant changes over time
were identified between molecular subtypes groups, or between pre- and post-menopausal status.
3.5 Discussion
These results show that DOTBIS measured features, such as 2C1# , change in accordance
with pCR status after 2-3 weeks under NAC. Our findings complement and extend previous smaller
studies conducted from 2007 to 2018 [134–143]. In a meta-analysis study [159], Liu et al reported
on the potential of diffuse optical spectroscopy for monitoring the response of patients with breast
64
Figure 3.10: 2C1# versus time (6 time points) by pCR group (pCR and non-pCR) for pre- and
post-menopausal groups. Smooth curve plot was computed by least-squares fitting.
cancer to NAC. Although a number of studies of diffuse optical spectroscopy and tomography have
been published, some dating back over 10 years, our clinical study represents one of the larger
studies of this topic to date and uses more modern criteria for pathologic response - both pCR
and RCB. As such, our study adds to the body of evidence reported for diffuse optical imaging
methods applied to breast cancer treatment response. Giving our larger sample size (n = 89),
and multiple imaging time points, we were also able to expand our analysis within the breast
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Figure 3.11: 2C1# versus time (6 time points) by pCR group (pCR and non-pCR) for each
molecular subtype breast cancer group (TNBC, HER2+ and HR+/HER2-). Smooth curve plot was
computed by least-squares fitting.
tumor subtypes. Overall, the data show a significant decrease in normalized values of 2C1
for patients with pCR in comparison to non-pCR, and such changes were noticed at the earliest
imaging time point (TP1). 2C1 can be attributed to tumor tissue oxygen consumption and it
is sensitive to cellular metabolism. Reduction in 2C1 levels represent the chemotherapeutic-
induced changes in the tumor microvasculature: lower 2C1 values associate with the reduction
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in tumor cell proliferation, and consequently in oxygen consumption, and might provide tumor
response prediction to NAC. However, different from previous publications [140, 160], our data
did not show any significant differences in changes of 2C$21 levels according to pCR status. It is
possible that 2C$21, which is more representative of vascular supply and oxygen delivery, could
be less variable to meet the demands of diminished cellularity due to cell death of the tumor tissue.
However, a larger study is necessary to confirm the actual biochemical significance of 2C$21
variation across NAC in comparison to 2C1.
By analyzing the results from the longitudinal multilevel mixed-effects, we observed that in
both three or six time-point imaging studies, 2C1 change differently over time between pCR
and non-pCR groups. It was important to move from the analysis of the data at each time point,
so we could get a more complex and inclusive picture of the 2C1 average trajectory over time
associated with tumor response. The mixed-effect modeling approach, as an advanced statistic tool,
allowed us to assume that each patient had a regression model characterized by subject-specific
parameters, which are molded by a combination of fixed effects parameters common to all patients
in the study and random subject-specific variability. The proportion reduction calculated from the
conditional growth model compared to the unconditional growth model with time as random slope
quantifies the amount of unexplained variance incorporate by the first one. However, there is still
more information that could be captured within such a study, and other parameters that researchers
might want to take into consideration in future studies to explain the high amount of variability
still taking place within the data.
The potential impact of molecular subtypes of breast cancer in the changes of DOTBIS - mea-
sured features across NAC was also evaluated. None of the previous studies investigated the
changes in optically derived parameters according to tumor phenotype. From the analysis at each
time point separately, HER2+ subgroup achieved the highest pCR rate and had the greatest signif-
icant 2C1 after 2-3 weeks under chemotherapy for pCR group. Notably, patients HR+/HER2-
breast cancer and residual disease had a significant increase in their 2C1 normalized levels after
NAC. For the TNBC subgroup, according to our findings, the best window to predict response is
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at the completion of the first four cycles of chemotherapy and using 2C)1 levels. However, from
mixed-effect modeling, molecular subtypes groups and menopausal status did not reach statistical
significance as predictors of 2C1 behaviour over time. A large study is necessary to confirm
these findings given that our study was limited by a small TNBC sample size (n = 17).
Our study has also some very minor limitations. Patient’s menstrual cycles at baseline was not
uniformly reported, and therefore were not accounted for analyses, which could cause variation in
the baseline hemoglobin measures. Tumor location selection was based on distance from the nipple
and quadrant information available from the patient’s radiology report. Same tumor position was
assumed for all the imaging time points. Tumor values were normalized by the non-tumor tissue
so any variability from inter and intra-patient analyses could be diminished. But no additional
work was done to consider the variations from different breast density groups. In addition, a larger
study population may enable to investigate the impact of different chemotherapy regimens and
draw better conclusion regarding the TNBC cohort. Finally, no data were reported for tumor sizes
bellow 1 cm, and there is no support that such technology could be used to assess changes in small
tumor volumes.
3.6 Conclusion
In summary, we found that 2C1 changes during NAC treatment. There are differences in the
time evolution of 2C1 between the pCR groups. These results confirm the potential of DOTBIS
for predicting patients that would most benefit from personalized therapeutic approaches, and the
need to investigate chemotherapy response prediction according to tumor phenotype. If further
validated on a larger set, these data could potentially be used to optimize response to NAC.
68
Chapter 4: NAC monitoring with Static DOTBIS - Contralateral breast
4.1 Introduction
The measurement of optically derived parameters in the affected breast is dependent on the
tumor location. DOT’s spatial resolution is relatively low due to its nonlinear, ill-conditioned and
ill-posed inverse problem [161]. By using a priori information provided by an additional high res-
olution anatomical imaging modality, such as magnetic resonance or X-ray could improve spatial
resolution. But adding another imaging modality would take away the low cost benefit associated
to DOT techniques [162]. Therefore, we also explored the potential of using DOT quantitative
measurement from the contralateral, non-tumor bearing breast to monitor NAC induced .
Otically-derived-parameters variations in contralateral non-tumor-bearing breast following NAC
have been previously studied by O’Sullivan et al. [144]. However, they did not correlated the ob-
served changes with the tumor response in the affected breast. Furthermore, a study published in
2005 [163] reported that chemotherapy can decrease contralateral breast cancer risk in younger
women [164]. But, it is still difficult to assess chemotherapy-related benefits for developing a
newly detected breast cancer due to the absence of an accurate quantitative metric.
The purpose of this study was to investigate the change tissue functional components, such
as hemoglobin concentration and water percentage, measured with DOTBIS in the contralateral
non-tumor-bearing breast of patients receiving NAC. We hypothesize that hemoglobin and water
values in the contralateral breast, which are directly related to tissue metabolism and vascular
characteristics, are associated with pCR to NAC. The analysis of the data at each imaging time




4.2.1 Analysis of each time point individually
Hemoglobin level reduction in the non-tumor bearing breast during NAC
A paired t-test was used to determine whether there was a statistically significant mean differ-
ence between DOTBIS parameters (i.e., 2C$21, 2C1, 2C)1, (C$2 and F0C4A) when mea-
sured at baseline compared to measurements performed after the completion of NAC. Treatment
with NAC resulted in a mean decrease of 3.19 (`") for 2C)1 levels (95% CI, 0.19 to 6.20
(`")), t(50) = 2.134, p = .038 and 2.07 (`") for 2C$21 levels (95% CI, 0.07 to 4.07 (`")),
t(50) = 2.080, p = .043, in the contralateral non-tumor-bearing breast. As shown by Table 4.1.
ctHHb, StO2% and water concentration also decreased, but their changes were not statistically
significant. Furthermore, changes were identified after just 2-3 weeks from starting NAC (TP1).
At TP1, 2C)1 levels were lower as compared to baseline measurements. We observed a statis-
tically significant mean decrease of 2.13 (`") (95% CI, 0.17 to 4.09 (`")), t(67) = 2.166, p
=.034. Also 2C$21 levels were lower at TP1, with an overall reduction of 1.57 (`") (95% CI,
0.23 to 2.91 (`")), t(67) = 2.339, p =.022. In addition, statistically significant mean decrease was
detected for 2C$21 levels at TP2 and TP4 in those receiving anthracycline-containing regimens.
Association of menopausal status with hemoglobin level reduction in the contralateral non-
tumor-bearing breast
At baseline, 52 patients (59.8%) were premenopausal women, 34 (39.1%) were postmenopausal
and for one patient (1.1%) her menopausal status was uncertain. An independent-samples t-test
was run to determine if there were differences in baseline DOTBIS parameters between pre- and
post-menopausal subjects. Pre-menopausal women had higher mean 2C)1 (33.30 ± 12.22 `")
than post-menopausal women (24.92 ± 7.78 (`")), a statistically significant difference of 8.39
`" (95% CI, 3.96 to 12.81), t(79) = 3.772, p < .0005. 2C$21 levels were also higher for pre-
menopausal women (19.36 ± 8.51 `") than post-menopausal (13.24 ± 4.89 `"). Different mean
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Table 4.1: Mean decrease in levels of 2C$21, 2C1, 2C)1, (C$2 and F0C4A in the contralat-
eral non-tumor bearing breast compared to their baseline values at each one of the 5 time points
measured after starting NAC regimen. Changes were noticeable at TP1. Bold values indicate
statistical significance at p <.05 level. Values are mean difference ± standard error.
Time Point
Mean difference compared to baseline at each time point





























































values were also detected for 2C1; post-menopausal women (13.99 ± 4.94 `") had lower val-
ues compared to pre-menopausal (11.77 ± 3.69 `"), p=.033. Difference in means for water was
also statistically significant between pre- (48.37 ± 9.33%) and post-menopausal (40.48 ± 12.14%)
patients, p=.001. StO2% mean value for pre-menopausal was higher (57.84 ± 9.61%) compared
to post-menopausal (54.26 ± 10.14%); however, it did not reach statistical significance (p =.112).
The menopausal status effect on hemoglobin and water reduction levels post-NAC treatment was
also evaluated. Pre-menopausal patients were more likely to show a higher 2C)1 and 2C$21
reduction after NAC. At the pre-surgical time point (TP5), 2C)1 levels were lower compared to
baseline measurements for the pre-menopausal group, a statistically significant mean decrease of
4.66 `" , (95% CI, 0.80 to 8.53 `"), p=.020. 2C$21 levels were also statistically significant
lower for the pre-menopausal at TP5, an overall reduction of 3.30 `" , (95% CI, 0.58 to 6.02
`"). No statistically significant changes were reported in the post-menopausal cohort. The pre-
menopausal group also had a statistically significant mean decrease of 4.45 `" for 2C)1 (95%
CI, 1.83 to 7.07 `"), p=.001 and 3.17 `" for 2C$21 (95% CI, 1.39 to 4.95 `"), p=.001 after
only 2-3 weeks of therapy. 2C1, F0C4A and (C$2 also decreased statically significant after two
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cycles of NAC for the pre-menopausal group as shown in Table 4.2.
Table 4.2: Mean changes for 2C)1(`"), 2C$21(`"), 2C1(`"), F0C4A (%) and (C$2(%)
in the contralateral non-tumor bearing breast compared to their baseline values at each one of the
5 time points measured after starting NAC regimen for both menopausal groups. Changes were
noticeable after just 2-3 weeks after NAC initiation for the pre-menopausal group. Bold values





Mean difference compared to baseline at each time point





























































































































Hemoglobin levels reduction in the contralateral unaffected breast and response to NAC
Thirty-seven subjects (42.5%) achieved pCR and 50 (57.5%) were classified as non-pCR. Fig-
ure 4.1 shows the mean ctO2Hb levels for all the patients, and both pCR and non-pCR groups
across the six imaging time points. Figure 4.2 (pCR) and Figure 4.3 (non-pCR) illustrate the
changes in ctHbT levels for two pre-menopausal patients imaged at three different time points
during NAC therapy.
Looking at the pCR group, NAC resulted in an overall decrease of 5.21 `" for 2C)1 (95%
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Figure 4.1: Mean 2C$21 levels (`") for all the patients (grey), and both pCR (blue) and non-
pCR (red) groups across the six imaging time points. Statistical significant difference was reported
at TP1 (baseline) and TP5 (pre-surgical) between pCR and non-pCR patients.
CI, -0.25 to 10.68 `"), p=.060. On the other hand, the non-pCR subjects had an overall mean
reduction of 1.99 `" for 2C)1 (95% CI, -1.71 to 5.70 `"), p=.281. However, for the changes
after 2-3 weeks of NAC (TP1), the pCR group presented statistically significant 2C$21 mean
reduction of 3.88 `" , (95% CI, 1.39 to 6.37 `"), p=.004. StO2 and 2C)1 in the healthy
contralateral breast were also statistically significant lower after 2-3 weeks of therapy for those
with pCR as shown by Table 4.3. At the same time point, the non-pCR group did not present
significant reduction for any of the DOTBIS parameters in the contralateral unaffected breast. After
finishing the first two cycles of AC (TP4), both groups had a significant mean decrease in 2C$21
levels compared to baseline, however, the pCR group (4.28 ± 2.19 `") had a nearly 2-fold greater
decrease than non-pCR (2.57 ± 1.14 `"). An independent t-test was run to determine if there
were differences in the 2C)1 reduction levels after 2-3 weeks of NAC between pCR and non-
pCR. 2C)1 reduction was greater in the contralateral healthy breast of those who achieved pCR
(4.97 ± 1.77 `") compared to non-pCR (0.37 ± 1.08 `"), a statistically significance difference
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Figure 4.2: Corresponding 2C)1 reconstruction maps for the contralateral unaffected breast of a
47 year old women who achieved pCR after TCHP therapy for HER2+ breast cancer. MIP images
(axial orientation) were acquired at baseline, after two-three weeks after NAC initiation (TP1) and
at pre-surgical time point (TP5). Overall mean 2C)1 after therapy was 15% lower compared to
baseline values.
Figure 4.3: Corresponding 2C)1 reconstruction maps for the contralateral unaffected breast of a
46 year old women who was classified as RCB III (non-pCR) after Tx12/ACx4 therapy for HER2-
breast cancer. MIP images (axial orientation) were acquired at baseline, after 2-3 weeks of NAC
(TP1) and at the pre-surgical time point (TP5). Overall mean 2C)1 after therapy was 11% higher
compared to baseline values.
of 4.62 `" (95% CI, 0.69 to 8.51 `"), t (66) = 2.049, p=.022. Mean reduction of 2C$21 at
TP1 was also statistically significantly different between pCR (3.88 ± 1.21 `") versus non-pCR
(0.14 ± 0.71 `"), p=.006. Additionally, mean change in water (p=.032) and (C$2 (p=.026) levels
were statistically significantly different between both groups. A Spearman’s rank-order correlation
was run to assess the relationship between the percentage change of hemoglobin levels at TP1
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for the contralateral unaffected breast and tumor volume. There was a statistically significant,
moderate positive correlation between contralateral 2C$21 and tumor 2C1 levels measured at
TP1 compared to baseline, AB(66) = .475, p < .0005. In addition, there was a positive correlation
between increase in 2C$21 levels from the contralateral breast and higher RCB score, AB(67) =
.270, p =.027.
Table 4.3: Mean decrease levels of 2C)1, 2C$21, 2C1, F0C4A and (C$2 in the contralateral
unaffected breast compared to their baseline values at each one of the 5 time points measured after
starting NAC regimen for both pCR and non-pCR groups. Changes were noticeable after just 2-3
weeks of NAC (TP1) for the pCR group. Bold values indicate statistical significance at p <.05
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4.2.2 Longitudinal multilevel mixed-effects model
The data frame for the contralateral multilevel mixed-effect model include all patients (= = 87)
measured at three time imaging time points: TP0, TP1 and TP5. The model has 2C$21 as the
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outcome/dependent variable, Days_of_NAC as the repeat measure, and PCR_bin, BMI and
Age as predictors/independent variables. One patient did not have age information available from
medical records, and 3 patients were not imaged at any of the three time points under analysis
(TP0, TP1 or TP5). The total number of observations was 203. Time was redefined as a categorical
covariate, so we could interpret whether 2C$21 changes at TP1 (after 2-3 weeks under NAC) or
TP5 (pre-surgery), and differ between pCR and non-pCR.
#STEP 1: Upload dataset
library("readxl")
Data1 <- read_excel("TP3_Long_Contralateral.xlsx", sheet=1)
Data1$Days_of_NAC <- factor(x = Data1$Days_of_NAC,
labels = c("TP0", "TP1", "TP5"))
#STEP 2: Open "nlme" package
library(nlme)
#STEP 3: Unconditional Model





The summary() results return the interaction between Days_of_NAC and PCR_bin, which
is significant at TP1, p = .0053, but not statistically significant at TP5. BMI, p= .0011, and Age, p=
.0015, values indicated a statistically significant negative relationship with 2C$21 levels: lower
2C$21 levels were registered for elderly and overweight/obese patients.
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summary(mod6)
## Linear mixed-effects model fit by maximum likelihood
## Data: Data1
## AIC BIC logLik
## 1278.445 1328.143 -624.2226
##
## Random effects:
## Formula: ~Days_of_NAC | Patient_Number
## Structure: General positive-definite, Log-Cholesky parametrization
## StdDev Corr
## (Intercept) 6.679693 (Intr) D__NAC
## Days_of_NACTP1 4.228971 -0.550
## Days_of_NACTP5 5.910416 -0.664 0.736
## Residual 2.005335
##
## Fixed effects: trans2 ~ Days_of_NAC * PCR_bin + BMI + Age
## Value Std.Error DF t-value p-value
## (Intercept) 33.40612 3.652379 116 9.146400 0.0000
## Days_of_NACTP1 -3.60323 0.967674 116 -3.723603 0.0003
## Days_of_NACTP5 -3.73203 1.323268 116 -2.820309 0.0056
## PCR_bin 0.76408 1.611744 79 0.474070 0.6368
## BMI -0.28608 0.084768 79 -3.374793 0.0011
## Age -0.17054 0.051876 79 -3.287371 0.0015
## Days_of_NACTP1:PCR_bin 3.53417 1.244372 116 2.840126 0.0053
## Days_of_NACTP5:PCR_bin 2.58868 1.700290 116 1.522494 0.1306
## Correlation:
## (Intr) Dy__NACTP1 Dy__NACTP5 PCR_bn BMI Age
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## Days_of_NACTP1 -0.181
## Days_of_NACTP5 -0.215 0.537
## PCR_bin -0.189 0.405 0.442
## BMI -0.615 0.004 0.002 -0.137
## Age -0.683 0.000 0.027 0.035 -0.050
## Days_of_NACTP1:PCR_bin 0.136 -0.778 -0.417 -0.524 -0.015 0.019










## Standardized Within-Group Residuals:
## Min Q1 Med Q3 Max
## -1.60219993 -0.26481211 -0.02195804 0.18872843 1.47782171
##
## Number of Observations: 203
## Number of Groups: 83
4.3 Discussion
We investigated whether the changes of DOTBIS features in the contralateral healthy breast
during NAC therapy are associated with therapy outcome in patients with stage II-III breast cancer.
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Figure 4.4: Top: Plot to illustrate the interaction between the mean response for two-way com-
bination of factors: Days_of_NAC and PCR_bin over 3 time points. Bottom: Box plots and
95% confidence intervals for 2C$21 in the three time point study separated by tumor response to
NAC: pCR (Left) non-pCR (Right) groups.
We observed that 2C$21 level are modifiable throughout the course of NAC. The magnitude of
change after only 2-3 weeks with the initiation of taxane-based regimen, associates with pCR
observed after 6 months of NAC.
Previous studies have demonstrated statistically significant changes in optically derived pa-
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rameters in breast cancer patients undergoing NAC and their correlation with tumor response [135,
137, 139, 165–168]. However, the majority of these studies looked at the tissue composition of
the tumor volume, and few of them used the contralateral healthy breast data as a normalizing
factor for the total tissue hemoglobin concentration within the tumor region. The measurement
of optically derived parameters in the affected breast is dependent on the selection of the tumor
location or region of interest (ROI). Yet, it is well known that breast optical imaging has limita-
tions regarding the spatial resolution. Therefore, the optically derived parameters collected from
the contralateral unaffected breast can potentially offer a more unbiased and non-ROI dependent
assessment. The only other two previous studies [144, 169] that evaluated optical imaging changes
during NAC in the contralateral normal tissue did not perform an analyses regarding associations
with tumor response. By associating contralateral healthy breast data with tumor response, we
could provide a potential marker for evaluating the efficacy of chemotherapy regimens early in the
treatment course.
Similar association with pCR is also reported in literature for background parenchymal en-
hancement (BPE) at breast magnetic resonance (MR) imaging in the contralateral normal breast.
In the last four years, several groups [170–173] have demonstrated an association between BPE
and tumor response after receiving NAC. Chen et al. found that BPE showed significant decrease in
those with pCR compared to non-pCR for pre/peri-menopausal patients after starting NAC [170].
Next, Preibsch et al. investigated the influence of chemotherapy on the degree of BPE and found
correlations between tumor response and qualitative assessment of BPE following NAC [171]. You
et al. also reported a positive association between overall BPE reduction at the early stage of NAC
and tumor response, especially in patients with hormone receptor-negative breast cancers [172].
The significant large reduction of DOTBIS-derived features for the premenopausal group may
be explained by the ovarian function suppression that affects estrogen secretion and leads to sec-
ondary change in breast tissue composition and its vascular characteristics [174, 175]. A re-
view published in 2005 [163] also concluded that younger women had much larger benefit from
chemotherapy than older patients potentially due to the ovarian ablation induced by chemother-
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apeutic agents. Fibroglandular tissue (FGT) and BPE-MRI were also reported as markedly in-
fluenced by menopausal status with significant decrease after menopause for the majority of the
women included in the study [176]. On the other hand, significant changes in DOTBIS-derived pa-
rameters for those with pCR regardless of their menopausal status could be also associated to the
direct damage of the vascular morphology and density in normal tissue caused by chemotherapy,
as investigated by Miller et al. [177].
In addition, the mixed-effect model results indicated a statistically significant negative rela-
tionship between 2C$21 and BMI. As already discussed, and also presented in the next chapter,
DOTBIS-measured 2C$21 is thought to be correlated to breast density, since it is related to the ar-
terial blood supply carrying oxygen to meet the fibroglandular tissue metabolic demand. Whereas,
BMI is inversely related to percent density and act as a co-founders of each other’s effects [178–
181]. In other words, overweight is correlate to greater amount of fat in the breast, which reflects
a larger area of non-dense tissue in the mammogram and, consequently, lower percent density
classification [180].
A limitation of our study was we did not reliably capture patient’s menstrual period during
treatment and around the time of scans. Besides that, since the majority of the patients in our
study did not have breast MR imaging before and after NAC treatment, we were not able to expand
our analyses to correlations between MR based quantitative measurements and DOTBIS features.
Finally, a larger study is also required to help us to identify potential optical predictors of long-term
outcomes in breast cancer patients who undergo NAC and understand the effect of chemotherapy
on reducing contralateral cancer risk.
4.4 Conclusion
In summary, this is the first study to confirm that optical derived metrics, measured by DOT-
BIS, in the contralateral non-tumor bearing breast tissue is modifiable with NAC treatment and its
changes are proportional to the degree of pCR after 2-3 weeks of taxane-based regimen.
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Chapter 5: Comparable optical-based image index of mammography breast
density
5.1 Introduction
One of the most well established imaging biomarker of breast cancer risk is mammographic
density [25–27]. Women with mammographically dense breasts have a higher risk of breast cancer
than women with less dense breasts [28, 29].The mammographic breast density (BD) equivalent in
breast magnetic resonance imaging (MRI) is fibroglandular tissue (FGT) and has also been shown
to correlated with breast cancer risk [182–184].
However, both X-ray mammography and MRI have several drawbacks. Mammography gen-
erates 2-dimensional (2D) images and the amount of breast density can vary due to changes in
positioning [185]. Given this limitation, mammogram has limited ability to quantify longitudi-
nal density variations accurately. In addition, its use of ionizing radiation restricts a long scale
screening. Breast MRI overcomes the limitations of mammogram providing 3-dimensional (3D)
evaluation of the fibroglandular tissue. However, high cost, intravenous injection, and long du-
ration of exam limits its routine use. In recent years, several groups [119, 120, 144, 186] have
shown evidence that optical based imaging modalities may play an important role in assessing
breast tissue composition by measuring optical property contrast from endogenous chromophores.
We hypothesize that diffuse optical tomography imaging provides quantitative measurements
of tissue functional components, such as 2C$21, which is directly related to tissue metabolism
and vascular characteristics, and could be correlated to mammographic breast density, a known
imaging biomarker of breast cancer risk [81]. In addition, we evaluate whether DOTBIS-measured
2C$21 concentration is modifiable after neoadjuvant chemotherapy (NAC).
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5.2 Results
We assessed BD from mammogram available before starting NAC. In total, forty patients had
available their BD measurements at baseline. Mammograms at our institution were performed
on dedicated mammography units (Senographe Essential, GE Healthcare). The views obtained
consisted of the standard mediolateral oblique and craniocaudal views. Additional views were
obtained if clinically indicated or requested by the reading radiologist. A breast fellowship trained
radiologist with 7 years of experience, blinded to the DOT measures, classified mammographic
breast density (BD) in accordance with BI-RADS categories: BD I = almost all fatty tissue, BD II
= scattered areas of dense glandular and fibrous tissue, BD III = heterogeneously dense and BD IV
= extremely dense.
BD I category was present in 2% of the patients (= = 1), BD II in 43% (17/40), BD III
in 53% (21/40) and BD IV in 2% (= = 1). Figure 5.1 displays the mammogram and DOTBIS
reconstructions at baseline for four subjects with different BI-RADS classification.
Spearman’s rank-order correlation was run to assess the relationship between DOTBIS-measured
water and hemoglobin concentrations at baseline, and mammographic breast density. As shown
by Table 5.1, there was a moderate positive correlation between baseline 2C$21 and BD, AB =
.486, p = .001. Baseline 2C)1, AB = .426, p = .006, and water percentage level, AB = .322, p =
.042, were also statistically significant correlated with breast density. After running multivariate
correlative analysis, 2C$21 combined to water percentage level was also associated with breast
density categories, AB = .497, p = .001.
A Kruskal-Wallis H test was conducted to determine if there were differences in baseline of
2C$21, 2C1, 2C)1, (C$2 and F0C4A percentage levels between the breast density groups,
Table 5.2. Median 2C$21 levels were the only parameter statistically significant different be-
tween BD groups, j2(2) = 9.374, p = .025, and increased from BD I (12.00 `M), to BD II (14.65
`M), to BD III (24.95 `M) to BD IV (35.00 `M), Figure 5.2. Subsequently, pairwise comparisons
were performed using Dunn’s procedure. A Bonferroni correction for multiple comparisons was
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Figure 5.1: Corresponding mammogram (MMG) and DOTBIS image. MIP images (axial orien-
tation) were acquired at baseline in the contralateral normal breast of 42-year-old women (BD I),
40-year-old women (BD II), a 36-year-old women (BD III) and a 46-year-old women (BD IV).
Nipples were excluded.
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Table 5.1: Baseline 2C$21, 2C1, 2C)1, (C$2 and F0C4A percentage (mean ± standard devi-
ation) for all the different BI-RADS classification and their specific Spearman’s correlation coeffi-













2C)1(`") 20.66 26.91 ± 9.58 35.76 ± 12.64 48.67 .426 .006
2C$21(`") 12.63 15.41 ± 5.84 21.88 ± 8.10 29.04 .486 .001
2C1(`") 8.00 11.50 ± 4.57 13.87 ± 6.02 19.63 .277 .084
F0C4A (%) 52.74 45.72 ± 9.15 51.14 ± 5.38 55.10 .327 .040
(C$2(%) 61.20 58.47 ± 6.01 61.60 ± 6.03 60.97 .205 .205
made with statistical significance accepted at the p < .008 level. This post hoc analysis revealed
statistically significant differences in 2C$21 levels between BD II and BD III, p = .007. No sig-
nificant results were available for the comparison with BD I or BD IV which is likely due to the
small sample size for both groups (= = 1 for BD IV and BD I).
Table 5.2: Baseline 2C$21, 2C1, 2C)1, (C$2 and F0C4A percentage (median) for all the
different BI-RADS classification. Bold values indicate statistical significance at p < .05 level
after running a Kruskal-Wallis H test to determine if there were differences in baseline DOTBIS-










(= = 1) p-value
2C)1(`") 10.00 15.76 24.05 37.00 0.57
2C$21(`") 12.00 14.65 24.95 35.00 .025
2C1(`") 8.00 18.12 22.24 37.00 .230
F0C4A (%) 24.00 15.76 23.71 30.00 .163
(C$2(%) 23.00 17.35 22.86 22.00 .542
Thirty-five patients were also imaged after their second cycle of NAC. The first two NAC cycles
elicited an overall decrease in 2C$21 levels in 60% (21/35) of the patients, whereas 40% (14/35)
participants had their 2C$21 levels slightly increased. Table 5.3 summarizes the mean values for
of 2C)1, 2C$21, 2C1, (C$2 and F0C4A percentage at three different time points: baseline,
after two cycles of taxol drug infusion and at the end of NAC. In Figure 5.3, using a grouped
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Figure 5.2: Simple box plot of 2C$21 (`M) in the contralateral breast at baseline for different
mammogram (MMG) breast density groups (I= almost all fatty tissue, II = scattered areas of dense
glandular and fibrous tissue, III = heterogeneously dense and IV = extremely dense). Group I
and IV had only one patient each. There was a moderate positive correlation between 2C$21 at
baseline and breast density (rs = .486, p = .001).
scatter plot and drawing a line of equality, we can interpret the overall 2C$21 reduction after two
NAC cycles (left), and after NAC completion (right). The patients lying on the line correspond
to contralateral breast tissue which experience no change to 2C$21 levels. Those above the line
were higher after two NAC cycles than before at baseline, i.e. display an increase in 2C$21, and
those below the line have experienced a reduction in 2C$21. One can notice that majority of
the patients are below the line. A paired-samples t-test was used to determined that there was a
statistically significant mean decrease in 2C$21 levels of 2.39 (95% CI, 0.67 to 4.11) `M after
two NAC cycles completion (17.04 ± 7.22 `M) in comparison with 2C$21 levels at baseline
(19.43 ±8.17`M), p = .008. The mean reduction of 3.22 (95% CI, 0.55 to 6.85) `M after NAC
completion (n=24) was also statistically significant, p = .024. Statically significant mean reduction
was also observed for 2C)1 after 2 weeks of therapy, p = .011, as shown in Table 5.3. Data are
mean ± standard deviation.
Out of these 35 subjects who were imaged at time point baseline and two weeks after NAC,
26 had their residual cancer burden (RCB) scores available after NAC. To explore any correla-
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Table 5.3: 2C$21, 2C1, 2C)1, (C$2 and F0C4A percentage (mean ± standard deviation) at
three different time points: baseline, after 2 cycles of taxol and at the end of NAC. Bold values
indicate statistical significance at p < .05 level after running a paired-samples t-test to determine if
there was a statistically significant mean decrease in the DOTBIS-measured features after 2 cycles
















2C)1(`") 31.94 ± 12.20 28.73 ± 11.20 30.82 ± 11.10 3.88 ± 1.44(p = .011)
5.13 ± 2.52
(p = .056)





2C1(`") 12.86 ± 5.50 11.71 ± 4.92 13.48 ± 5.29 1.47 ± 0.74(p = .056)
1.43 ± 1.28
(p = .276)
F0C4A (%) 48.98 ± 7.60 46.99 ± 11.36 48.83 ± 7.12 2.31 ± 1.53(p = .141)
0.3 ± 0.1
(p = .765)





Figure 5.3: Left: Grouped scatter plot 2C$21 before third NAC cycle (n=35). Right: Grouped
scatter plot for reduction comparison between 2C$21 (`M) at baseline versus after NAC com-
pletion (n=24).
tion between changes in DOTBIS-measured parameters after 2 cycles of chemotherapy and tumor
response, we run an independent-samples t-test to evaluate whether there was a difference be-
tween responders (RCB0) and non-responders (RCBI, II and III). The reduction levels of 2C$21,
2C1, 2C)1, (C$2 and F0C4A percentage were not statistically different between responders
and non-responder tumors. For instance, the results show a mean difference of 1.80 ± 2.44 `M
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in 2C$21 levels after 2 weeks of NAC between responders and non-responders, but it is not
statistically significant (p = .468).
The association with age was analyzed by considering 2C$21 levels at baseline for all the
40 patients. A linear regression fitting indicates a moderate negative correlation between baseline
2C$21 and age (r = -.439, p = 0.005). From the coefficient of determination, A2 = .20, we can
determine that 20% of the variability in baseline 2C$21 is explained by patient age at enrollment,
Figure 5.4.
Figure 5.4: Mean values of 2C$21 levels across NAC therapy for the patients imaged at all the 3
time points (n=18).
5.3 Discussion
In our study, there was a moderate positive correlation between 2C$21 and patient’s mam-
mographic density classification. Baseline ctTHb and water percentage level were also statistically
significant correlated with breast density. High levels of 2C$21 can be associated with the in-
creased rate of metabolism in dense breasts due to the greater volume fraction of fibroglandular
tissue compared to almost entirely fat, and the increased vascular demand required by dense tis-
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sues. Additionally, the moderate correlation with water can be related to higher water fraction in
fibroglandular tissue compared to adipose tissue [187]. This observation indicates that the 2C$21
levels measured by DOTBIS may be a novel biomarker of breast cancer risk.
Previous publications, summarized by Grosenick et al in their review of optical breast imaging
and spectroscopy [125], have shown the feasibility of optically derived data to quantify breast
density. Simick et al. categorized density measurements into two groups and presented a PCA
model that predicts lower from high-density tissues with 80% of accuracy [145]. In addition,
Blackmore et al. correlated breast tissue optical content ((C$2, ;8?83 and F0C4A) with percent
density in pre- and post-menopausal women [146]. In a simulation study, Ruiz et al. found that
estimated percent breast density predicted from lipid and water maps was highly correlated to the
true values from MRI [147]. Moreover, Fang et al. found linear correlation between ctTHb and
the fibroglandular volume fraction derived from the 3D digital breast tomosynthesis imaging scans
[148]. However, none of these references specifically correlates the optical data with the four breast
density groups from BI-RADS classification, or investigates the changes across NAC treatment.
Similar to our study, O’Sullivan et al. demonstrated a moderate correlation between ctTHb
level and FGT assessed by MR imaging, r = .597, p = .040 [144]. However, they did not find
significant correlation with BIRADS classification of mammographic breast density, possibly due
to lower number of patients in their study (= = 12). They observed significant difference between
mean hemoglobin levels in BD II and BD IV, and water percentage levels in BD III and BD IV. With
the larger sample size in our study (= = 40), we were able to detect a significant difference in mean
2C$21 levels between BD II and BD III, a result not observed previously. In addition, unlike our
study, the diffuse optical spectroscopy imaging system used in their study did not sample the entire
breast volume, and it is unclear if the nipple region was excluded, which can impact accurate
assessment due to varied levels of 2C$21 involving the nipple. Taroni et al. also published a
work showing direct correlation between mammographic breast density BI-RADS classification
and water, lipid and collagen content. However, for a sample size of 49 patients, the correlation
between breast density and 2C)1 or (C$2 were not statistically significant [120]. It is important to
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highlight that the lacking of strong correlation with BI-RADS classification could also be justified
by the qualitative measurement approach associated to this type of breast density assessment. High
variability between radiologists are expected [188] and quantitative measurements of breast density
could reveal stronger association with the optical features.
Because optical imaging provides quantitative metrics capable to measure and track changes
in breast tissue composition, we reconstructed the 3D full volume of 2C$21, 2C1, 2C)1,
(C$2 and F0C4A percentage maps of 40 patients undergoing NAC treatment to determine whether
this metric is modifiable. Our results indicate significant reduction in 2C$21 levels after NAC
completion. Several studies have reported a consistent reduction of breast density after NAC [189–
192]. By using MRI or mammographic imaging, all these groups were able to detect change in
percent breast density across NAC. For example, Chen et al., using 3D MR imaging, demonstrated
that patients who underwent AC and taxane had a mean percentage reduction of 12.7% at the
end of NAC [190]. Besides, Sandberg et al. and Knight et al. took a step further and showed
that women who experienced a decrease of at least 10% in breast density after chemotherapy or
tamoxifen, had decreased their risk in half of contralateral breast cancer. According to the litera-
ture, chemotherapy, including taxane based regimens, has been linked with amenorrhea and ovar-
ian function suppression. The rapid reduction in estrogen from chemotherapy induced menopause
contributes to secondary change in breast tissue composition, and consequently, an impact in mam-
mographic breast density [174, 175]. In similar fashion, our results showed that 2C$21 measured
by DOTBIS is also modifiable with NAC and it had a significant mean reduction of 12% after the
first 2 cycles of NAC and approximately 17% at the end of NAC. However, no statically signif-
icant reduction was noticed in 2C1 levels. Similar finding was published by O’Sullivan et al.
in the same work discussed before. The reduction of 2C$21 levels and no significant changes
in 2C1 might suggest that NAC induces reduction of blood perfusion by vascular damage, and
consequently, breast density reduction. It is possible that 2C$21, which is more representative
of arterial blood supply carrying oxygen to the breast tissue, could be more variable to meet the
demands of the amount of fibroglandular tissue, resulting in a positive moderate correlation. While
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2C1, which is predominantly venous blood that carries away metabolic byproducts including
deoxygenated blood after tissue consumption, may be less variable and resulting in non-correlation
with the amount of fibroglandular tissue in our small sample size. While O’Sullivan et al. found
statically reduction in 2C$21 levels about 90 days after start of NAC, we found a significant
reduction already after 15 days. Since all patients in our study were administered taxane based
regimen for the first weeks of treatment, we believe that same treatment type was responsible to
minimize any variability from drug-induced changes in the breast tissue, and improved the intra
and inter-patient analyses.
Regarding correlations between changes in the hemoglobin levels and tumor response to NAC,
our results showed that the reduction levels of 2C$21, 2C1, 2C)1, (C$2 and F0C4A percent-
age were not statistically different between responders and non-responder tumors. However, after
running a statistical power analyses using G*Power 3.1, a sample size of at least 40 patients would
be necessary to see a statistically significant difference in the changes of 2C$21 levels between
these two subgroups with an 80% power. Given that our study was limited by a small sample size
with RCB scores available (n = 26), the statistical power to detect such a difference in 2C$21
between the two groups was only 47%. Therefore, further studies are needed to demonstrate how
DOTBIS-measured parameters change within the context of response to NAC.
We also examined the relationship between baseline 2C$21 and age. Breast density is known
to decrease with increasing patient age due to postmenopausal alteration of glandular breast tissue
[193, 194]. Our results presented similar association. There was a significant inverse relationship
between age and 2C$21 measured at baseline (p < 0.005). As already discussed, breast tissue
becomes less dense with age, therefore the correlation between the lower levels of 2C$21 might
be related to the reduced vascular supply and perfusion occasioned by less fibroglandular tissue
present in the breast of the older women.
Major limitation of our study was its dependence on the patient’s mammogram availability for
her inclusion in the study. The protocol at our institution does not include a post-NAC mammo-
gram, and we were not able to have an end-point correlation between 2C$21 and mammographic
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breast density. Patient’s menstrual cycles at baseline was not uniformly reported, and therefore
were not accounted for analyses, which could cause variation in breast tissue composition and
density assessment. In addition, we were not able to expand our analyses to correlations between
MR based quantitative breast density measurement with 2C$21 since the majority of the women
in our cohort did not had access to MR screening at pre-NAC time point. Furthermore, our study
population was already diagnosed with breast cancer. Further studies in BRCA mutation carriers, a
high-risk group, are needed to correlate DOTBIS-measured 2C$21 with breast density and how is
related to cancer risk. If such a relationship can be established, it may be possible to use DOTBIS
measurements to predict breast cancer risk.
5.4 Conclusion
Optical-based image index by DOTBIS may be a novel modifiable marker of breast cancer
risk that is 3D quantifiable and without exposure to ionizing radiation. Potential for its use as a
predictor of breast cancer risk as well as an assessment tool to longitudinally evaluate efficacy of
various chemoprevention strategies is warranted.
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Chapter 6: Bilateral Dynamic DOTBIS Measurements
6.1 Introduction
After successful implementation of tools that are necessary to extract useful metrics from dy-
namic studies, we also need to explore the relationship between this features and the different
natural mechanisms of arteries, veins and microvessels in biological tissue. Therefore, the overall
goal of dynamics DOTBIS is to investigate interactions between tissue and its blood supply. This
is possible due to the fact that hemoglobin, the principal chromophore affecting the dynamics of
NIR range transmission in breast tissue, is also the main factor responsible for oxygen transport
to tissue. Comparisons between different trends in hemoglobin time-trace are performed during a
breath hold followed by a recovery state. Upon a breath hold, it is expected a rise in venous return
pressure, which will cause an increase in tissue blood volume [195].
In this chapter, we explored the clinical utility of the dynamic features of data acquired with
DOTBIS. Similar to our efforts in previous parts of this thesis, we look for longitudinal differences
between pCR and non-pCR patients in the tumor volume induced by chemotherapy agents. In
addition, we try to identify temporal enhancement pattern of the breast tissue during a breath
hold that potentially provide new features for breast tissue permeability. We hypotisise that these
features could be associated to pCR. Finally, we will test if a combination of HER2 status, dynamic
features, and static features can be employed for pCR prediction before starting NAC.
6.2 Results - Part I: Longitudinal multilevel mixed-effect model
Quantitative dynamic parameters, Table 6.1, were determined from the tumor-volume 2C)1
time-trace acquired during breath hold (ascending curve) and recovery (descending curve), and its
sigmoid function approximation.
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Table 6.1: Summary of all the dynamic features acquired from breath hold and recovery hemody-
namic time-traces.
Dynamic feature name Symbol
Flow-in slope g8=
Washout slope g>DC
Time to reach 90% of the maximal signal intensity )90
Slope at the steepest part of the breath hold (ascending) curve d
Point of inflection in the breath hold (ascending) response curve )1
2

Slope at the steepest part of the recovery (descending) curve d
Point of inflection in the recovery (descending) response curve )1
2

To identify the independent features at baseline, a Pearson correlation was run to assess if there
were linear dependencies on any pair of dynamic parameters. Table 6.2 shows the correlation
results for all feature pair combinations. )90 and g8= were removed from further analyses due to
high correlation (r≥ 0.5) to d, and g>DC , respectively.
Table 6.2: Pearson correlation results for all feature pair combinations. )90 and g8= were highly
correlated (r≥ 0.5) to d, and g>DC , respectively.




































































































The main interest is to evaluate the average longitudinal evolution for each one of the five
independent dynamic features (i.e. g>DC , d, )1
2
, d and )1
2
) once we correct for pCR status
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classification. Therefore, five models were built, one for each outcome under analysis. Out of the
58 patients under Tx12 / ACx4 and T/Cx12 / ACx4 regimens, 55 were analyzed (three patients had
static measurements performed, but not dynamic measurements), and there were 229 observations
in total. Time, Days_of_NAC, was the repeat measure and redefined as a categorical variate, so
we could interpret whether the dynamic features change at TP1, TP2, TP3, TP4 or TP5, and differ
between pCR and non-pCR. PCR_bin, BMI, molecularSubtype and Age were considered
as predictors/independent variables.
By following the same steps introduced previously in Chapter 3 and Chapter 4, the results





 and d were the only dynamic features to show significant difference along time, Figure
6.1. For all these 3 features, difference between pCR and non-pCR was detected at the end of
the taxane cycle (TP3). In addition, for )1
2
 , statistical difference was found at TP4, after one
AC dose administration. Figure 6.2 shows a comparision between two patients (P43 and P60),
both under the Tx12 / ACx4 therapy. As one can see, there are significant changes from )1
2

baseline measurement to )1
2
 measurement after taxane cycle is finished (TP3) between different
pCR patients. While pCR tumor has faster time response at the recovery stage at TP3, the non-pCR
tumor has a increased delay. BMI was statistically significant in the average longitudinal evolution
of all the three features (? ≤ .05 for all the models), and it indicates a negative relationship with
the dynamic features: lower values were registered for overweight/obese patients across time. No
statistical difference was found for the 3 time-point study.
6.3 Results - Part II: Pre-treatment feature and tumor response prediction to NAC
2C)1"-50% measured at baseline (TP0), before starting NAC therapy, was used to generate
multiple threshold levels, ranging from 1 to 5, to determine the optimal cutoff point for DOT-
THbE% quantification that best correlated with the binary pCR and RCB classification, Figure
6.3. There was a moderate positive correlation, as defined by Cohen’s general guidelines [196],
between DOT-THbE% and pCR or RCB classification at all threshold levels, except at x1.0 for
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 (middle), and d (bottom) for 20 pCR and 35 non-pCR patients
obtained at all 5 time points. Difference between both groups was detected at the end of the taxane
cycle (TP3) for all of these three dynamic features. )1
2
 was also statistically different between
pCR and non-pCR patients after one AC dose administration (TP4).
pCR group, Table 6.3. The highest correlation was noted at threshold level of x3.5 for both pCR
and RCB classification.
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Figure 6.2: 2C)1 time-trace during breath hold and recovery for a patient with pCR (P60) and
patient who did not have a pCR (P43). Changes from )1
2
 baseline measurement (solid line) to
)1
2
 measurement after taxane cycle is finished (TP3) (dashed line) between different pCR patients.
While pCR tumor has faster time response at the recovery stage at TP3, the non-pCR tumor has a
increased delay.
An independent t-test was performed to determine if there were differences in DOT-THbE%
at x3.5 threshold level between pCR and non-pCR tumors. DOT-THbE% was higher to non-pCR
(19.49 ± 10.26) than pCR (13.30 ± 6.50), a statistically significant difference of 6.19 (95% CI, 2.32
to 10.07), t(82) = 3.376, p =.001.
Furthermore, a one-way analysis of variance was conducted to determine if DOT-THbE% was
different for the four RCB groups. DOT-THbE% was statistically significantly different between
different RCB groups at the x3.5 threshold level, F (3, 76) = 5.814, p = .001, Table 6.4. DOT-
THbE% levels increased from the RCB 0 group (13.27 ± 6.59), to RCB I (14.55 ± 9.22), to RCB
II (19.06 ± 10.29), to RCB III (25.29 ± 10.63), in that order. Tukey post hoc analysis revealed that
the increase from RCB 0 to RCB III (12.02, 95% CI (3.77 to 20.27)) was statistically significant (p
= .001), as well as the increase from RCB I to RCB III (10.74, 95% CI (0.17 to 21.30), p = .045),
Table 6.5, but no other group differences were statistically significant. Data is presented as mean
± standard deviation.
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Table 6.3: Correlation analysis between DOT-THbE% and RCB or pCR classification. DOT-
THbE% significantly correlated with tumor response classification at all threshold level (except x1
for pCR classification) with the highest at x3.5 cutoff level (bold).
DOT-THbE% values
x1 x1.5 x2 x2.5 x3 x3.5 x4 x4.5 x5
pCR group .173 .223* .266* .305** .323** .331** .330** .329** .325**
Significance .116 .041 .014 .005 .003 .002 .002 .002 .003
N 84 84 84 84 84 84 84 84 84
RCB score .243* .303* .353** .394** .411** .417** .417** .417** .415**
Significance .030 .006 .001 .000 .000 .000 .000 .000 .000
N 80 80 80 80 80 80 80 80 80
* Correlation is significant at the 0.05 level (2-tailed).
** Correlation is significant at the 0.005 level (2-tailed).
6.3.1 Deep learning-based prediction of tumor response to NAC
Random Forest [197] is a classification algorithm that consists of an ensemble of decision trees.
Decision Tree is a supervised machine learning techniques that classifies the information along
various branches [198]. Each node of the tree is formed by selected attributes, which minimize as
much as possible mixture arrangements of classes between the subsets created by the test. This
process is repeated until reaching an unique class (the tree leaf) [199]. However, by using recursion
from the divide and conquer data structure, and not limiting tree growth, Decision Trees tend to
overfit the training data. Random Forests address this issue by performing multiple decision trees,
and the output is an average of the individual decision tree predictions [200].
We applied a Random Forest learning method to predict pCR from pre-treatment (at baseline)
DOTBIS scan features. In this analysis, optical data from 88 patients were randomly split into a
training set of 66 patients (75%) and a testing set of 22 patients (25%), Figure 6.4. For establishing
how many features to add to the model, we followed the ratio 4# 5 > #>, where # 5 is the number
of features, and #> is the number of observations. Given the number of observations in our training
set was 66, the maximum number of features would be four, so we can try to minimize overfitting
from data becoming sparser as we increase the number of features considered.
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Figure 6.3: Top: plot of the p-value profiles of paired Student’s test comparing the DOT-THbE%
mean, at different threshold levels (ranging from 1 to 5), between pCR and non-pCR groups. The
best cutoff factor was x3.5, and the mean difference between both groups was 6.19, 95% CI(2.54
TO 9.84), p = .001. Bottom: plot of the ANOVA profiles comparing the DOT-THbE% mean, at
different threshold levels (ranging from 1 to 5), between the four RCB groups. The best level was
at x3.5, F (3, 76) = 5.814, p =.001. Differences were detected between RCB 0 and RCB I to RCB
III.
The algorithm was implemented by using the randomForest package available in R coding.
PCR_bin (tumor response classification to NAC, 0 is pCR and 1 is non-pCR) was established as
the parameter we are interest in predicting. The number of trees to be generated was set to 100. The
features used in the construction of each tree are selected randomly ("random forest") from Cx3.5
(DOT-THbE% feature at the x3.5 threshold level), norm_tumor_Hb_W0 and HER_STATUS
(features available before patient starting NAC). Selection was based on best performance from a
static norm_tumor_Hb_W0 and) and dynamic feature (Cx3.5) at baseline, and tumor molecular
profiling (HER_STATUS). To assess performance of our classifier, both confusion matrix and ROC
curve analyses, Figure 6.5, were executed. Classification sensitivity and specificity were 67% and
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Table 6.4: One-way analysis of variance (ANOVA) test to analyze the effect of DOT-THbE% at
various threshold levels on differentiating the four RCB goups. The best level was at x3.5, F (3,
76) = 5.814, p = .001 (bold).
Sum of Squares df Mean Square F Significance
x1 Between groups 1383.544 3 461.181 2.827 0.044
Within groups 12397.830 76 163.129
Total 13781.374 79
x1.5 Between groups 1568.047 3 522.682 3.559 0.018
Within groups 11160.283 76 146.846
Total 12728.331 79
x2 Between groups 1614.259 3 538.086 4.402 0.007
Within groups 9289.817 76 122.234
Total 10904.077 79
x2.5 Between groups 1612.623 3 537.541 5.358 0.002
Within groups 7624.153 76 100.318
Total 9236.776 79
x3 Between groups 1488.126 3 496.042 5.709 0.001
Within groups 6603.642 76 86.890
Total 8091.768 79
x3.5 Between groups 1336.251 3 445.417 5.814 0.001
Within groups 5822.484 76 76.612
Total 7158.735 79
x4 Between groups 1180.957 3 393.652 5.767 0.001
Within groups 5188.030 76 68.264
Total 6368.987 79
x4.5 Between groups 1047.581 3 349.194 5.753 0.001
Within groups 4613.188 76 60.700
Total 5660.768 79
x5 Between groups 925.655 3 308.552 5.709 0.001
Within groups 4107.830 76 54.050
Total 5033.485 79
100%, respectively. The accuracy of pCR prediction among all patients was 87.5% (95% CI,
0.6165, 0.9845, p =.029), with PPV = 100% and NPV = 83%.
6.4 Discussion
Besides being able to acquire estimates of absolute tissue optical properties, DOTBIS is also
suitable to explore the temporal dynamics of breast tissue from induced changes in the hemoglobin
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Table 6.5: One-way analysis of variance (ANOVA) with Tukey post hoc analysis to compare dif-
ferences between RCB classes. Baseline 2C)1"-50% was used to generated multiple threshold
levels, ranging from 1 to 5, to determine the optimal cutoff point for DOT-THbE% quantifica-
tion that best correlate with the binary pCR and RCB classification. Showing best level at x3.5
threshold level, RCB 0 and RCB I has a statistically significant difference from RCB III (bold).
95% Confidence Interval
RCB class Mean Difference Std. Error Sig. Lower bound Upper bound
x3.5 0 1 -1.2857 3.2713 .979 -9.8787 7.3072
2 -5.7952 2.2662 .059 -11.7479 .1575
3 -12.0234 3.1385 .001 -20.2675 -3.7792
1 0 1.2857 3.2713 .979 -7.3072 9.8787
2 -4.5094 3.3851 .546 -13.4014 4.3826
3 -10.7377 4.0216 .045 -21.3017 -.1736
2 0 5.7952 2.2662 .059 -.15759 11.7479
1 4.5094 3.3851 .546 -4.3826 13.4014
3 -6.2283 3.2570 .232 -14.7836 2.3270
3 0 12.0234 3.1385 .001 3.7792 20.2675
1 10.7377 4.0216 .045 .1736 21.3017
2 6.2283 3.2570 .232 -2.3270 14.7836
signal, and to evaluate non-invasively tissue vascular dynamics.
As expected from the dynamics traces, 2C)1 levels increase upon the breath hold due to the
increase in tissue blood concentration linked to the rise in venous return pressure from the in-
creased intrathoracic pressure. From the longitudinal analysis for the dynamic features extracted
from the 2C)1 time-trace, we did not observed any difference at baseline between pCR groups.
However, their time evolution, specially when looking at the )1
2
 feature, gets significant different
after taxane drug cycle administration is completed (TP3). As presented, in contrast to the non-
pCR group, pCR patients had a faster time response during recovery. As a chemotherapeutic drug,
taxanes disrupts microvessels and decreases microvascular density [201]. Given that chemother-
apy agents reduces breast tumor cell density, which in turn lowers interstitial fluid pressure, and
consequently increases blood vessel diameter and blood flow velocity [202], we expect to observe
an increase in blood flow velocity inside the vessels when a tumor responds to taxanes. Therefore,
our data supports the hypothesis that the increase apoptosis and decrease interstitial fluid pressure
101
Figure 6.4: Diagram of the predictive model proposed for pCR classification using Random Forest
learning method. Model evaluation is performed using a testing subset that was not previously
used to train the model. Testing set was 25% of the entire number of observations (n = 88).
in responding tumors to taxane may cause the increase in faster time response at the end of the
breath hold (tumor 2C)1 values decay faster to 50% level during recovery).
The origin of the DOT-HbE% dynamic feature was based on the analysis of the temporal en-
hancement pattern of the breast tissue following a period of transient hypoxemia, via a simple
breath hold. This is achieved by the acquisition of DOTBIS scans of baseline (before starting
NAC), and comparision between the reconstruct 2C)1 3D map at the end, and at the half of the
breath hold window. The difference between these two time points relies on the tissue vasculariza-
tion, permeability of the vessels, and blood flow. Our results show that DOT-HbE% is significant
different between pCR and non-pCR, and RCB groups. Complete response to NAC or minimum
residual invasive disease (RCBI) was associated to lower levels of DOT-HbE%. We believe that
tumors that will develop resistance during the course of NAC regimen have worse tissue perme-
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Figure 6.5: Area under the receiver operating characteristic curve (AUC) for the Random Forest
classifier to predict pCR from pre-treatment (at baseline) features combined to HER2 status. For
these results, a validation cohort (independent from the training cohort) of 22 patients was used.
ability characterized by high accumulation of blood in the DOTBIS scans at the end of the breath
hold, and increased DOT-THbE% values, consequently. As discussed in literature [170], a poor
blood perfusion may impair chemotherapy agent delivery into the breast leading poor response.
Aligned to other MRI studies [173, 203], we also hypothesise that the normal breast tissue beyond
the tumor volume may affect tumor pathogenesis and treatment response since, as already reported
in literature [204], drug therapy distribution may be limited if they cannot penetrate tumor tissue
due to compromised surrounding structures’ vasculature supplies. Therefore, breast tissue outside
tumor margins may play a critical role in determining response to NAC.
We also demonstrated that a combined static (2C1), dynamic (DOT-THbE%), and molec-
ular feature (HER2 status) model approach yielded an unique signature of response prior to NAC
administration to enable enhanced pCR prediction. Other studies have demonstrated compara-
ble frameworks to our study. With similar validation cohort (n = 22) [205], baseline tumor total
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hemoglobin content values, which were acquired from a near-infrared imager coupled with an ul-
trasound, showed an AUC of 0.88, 0.69 and 0.72, within each tumor subtype, HER2+, ER+ and
TNBC, respectively. Tran et al. also observed an AUC of 0.821 for oxy-hemoglobin acquired
from diffuse optical spectroscopy texture feature, and using naive Bayes model [140]. However,
sample size was limited (n=37), and no independent validation cohort was available. Additional
pretreatment pCR prediction is available in literature for other imaging modalities [206–211]. For
example, Braman et al., from pretreatment breast DCE-MRI, found an AUC = 0.714 (n = 21)
among all molecular subtypes [210]. Lastly, in a smaller study (n = 24, and no independent vali-
dation set), and using quantitative ultrasound methods to assess the effectiveness of chemotherapy,
the authors found an AUC = 0.82 after second NAC dose. But, no statistical analyses was signifi-
cant at baseline [211].
6.5 Conclusion
In conclusion, we found that DOTBIS dynamic features show different longitudinal evolution
along NAC treatment between pCR and non-pCR tumors. Further, we identified a novel pretreat-
ment feature based on temporal enhancement pattern of the breast tissue during a breath hold.
This new feature combined with static baseline deoxy-hemoglobin and HER2 status contributed to
successful prediction of pCR from pretreatment imaging. Although we were able to demonstrate
good performance on pCR status prediction with an independent validation set, these findings
need to be confirmed within a larger cohort, and from multiple external sites. Pretreatment pCR
prediction would dramatically change breast cancer therapy management and chemotherapy drug
development.
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Summary and Future Work
In this thesis, DOTBIS data was collected and analyzed from 105 patients with stage II-III
breast cancer who underwent up to 6 months of neoadjuvant chemotherapy (NAC). This data was
used to determine hemoglobin and water values at different time points during the course of NAC.
By combining features derived from DOTBIS with information about patient demographic, tu-
mor response to NAC, and tumor molecular subtype, this work offers a comprehensive analyses
of the chemotherapy-induced changes in breast tissue metabolism. Bilateral measurements were
performed in all patients, and both tumor and non-affected tissue were analyzed volumetrically.
Longitudinal studies were performed to evaluate and understand the changes in tissue metabolism
during NAC and the differences in time evolution between pCR and non-pCR groups. Pretreatment
pCR prediction analyses were also performed and open new possibilities to integrate DOT imag-
ing in the future of precision medicine. The main contributions of this work can be summarized as
follows:
• Automated code for tumor selection and nipple removal from DOTBIS 3D maps.
• Conception of a new feature, DOT-THbE%, based on the temporal enhancement pattern
of the breast tissue following a period of transient hypoxemia (breath hold). DOT-THbE%
value for non-pCR group was higher when compared to pCR at baseline (before starting
NAC). A significant difference of 6.19, p =.001
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• A proposed model combining DOT-THbE% with baseline deoxy-hemoglobin and HER2 sta-
tus offered pre-treatment pCR prediction to NAC. After validation using an independent and
randomly selected patient cohort (n=22), the prediction model had an overall pretreatment
prediction accuracy of 87.5%, with PPV = 100% and NPV=83%.
• From contralateral breast data, oxy-hemoglobin levels were statistically significant corre-
lated with mammographic breast density (A( =.486, p = .001), and may be a novel compara-
ble optical-based image index of mammographic breast density.
• DOTBIS measured features from the tumor and contralateral breast are modifiable with NAC
regimen, and its changes are proportional to the degree of pCR after 2-3 weeks of taxane-
based regimen.
There are some research topics that arise from this work and could be pursued in the future.
First, a new clinical study should be proposed in order to establish a relationship between DOTBIS-
measured oxy-hemoglobin and breast cancer risk prediction. Our current study population was
already diagnosed with breast cancer. Therefore, a next step would be designing future studies
in BRCA mutation carries, a high-risk breast cancer group, to evaluate the prediction value of
DOTBIS features in risk assessment.
A second line of research, which follows from Chapter 6, is to investigate whether optical
imaging quantitative metrics to measure changes in breast tissue and density may correlate with
qualitative MR imaging BPE assessment. After running correlation tests between BPE and the
DDOT parameters for the our patient cohort no significant result was found. This reinforces
the need for a more robust BPE equivalent optical signature that results from a combination in-
dex correspondent to increased vascular density, perfusion and oxygen consumption, which in
optical imaging could be associated to measurements of oxygenated hemoglobin, deoxygenated
hemoglobin, water concentrations or qualitative analyzes of dynamic traces from oxygenated and
deoxygenated hemoglobin curves acquired during a breath hold. The optical imaging correlation
with BPE would be of great impact since BPE is thought to be a measure of blood flow in the dense
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tissue due to vascular perfusion and may represent breast tissue activity. From this association, it
would be possible to develop a marker of physiologically active breast tissue that is more likely
to respond to NAC or undergo malignant transformation, which can also give us a possibility of a
new breast cancer risk biomarker.
Finally, given the five years experience conducting this clinical study, few adjustments should
be considered in the future to improve the study performance and patient comfort. Machine-user
interface should be simplified and more user friendly. The current program has many unexpected
errors when given a different order execution that can jeopardize data acquisition or data file saving.
These errors are simple to avoid, or detect, for a trained PhD student with 3 years of experience,
but might be confusing and non-approachable for a clinical technician with minimum experience.
Next, patient interface based on the two sets of four rings works surprisingly well to accommodate
different breast sizes, and for the past years, I have never had to decline imaging a patient due to
size issues. However, the customization procedure is one of the most time consuming step during
imaging acquisition, and one of the most harmful practice that leads to fiber damage. Future design
work would be necessary for translating the personalizing ring position work from a mechanical
to a more automatic process. In addition, approximately 20% to 30% of our patients complained
of knee or back pain during the imaging. Additionally design is desirable to improve patient
comfort during DOTBIS scans. A lay down setup or wearable interface could offer a more positive
experience for the patient during imaging, and improve engagement for longitudinal studies with
multiple imaging time points.
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Appendix B: Longitudinal Data Analysis Script and Output - Chapter 3
#PART I - Conditional growth model (mod4)
#STEP 1: Upload dataset for the 3 time -point
library (" readxl ")
Data1 <- read_excel (" TP3_Long.xlsx", sheet =1)
Data1$Days_of_NAC <- factor(x = Data1$Days_of_NAC ,
labels = c("TP0", "TP1", "TP5"))
#STEP 2: Open "nlme" package
library(nlme)
# STEP 3: Conditional growth model
mod4 <- lme(HHb_N~Days_of_NAC*PCR_bin + MenopausalStatus +
molecularSubtype ,random =~ Days_of_NAC|Patient_Number ,
data=Data1 ,method ="ML", control=lmeControl(opt='optim '),
na.action=na.exclude)
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# STEP 4: Displaying our results - Full model: 3 time points
summary(mod4)
## Linear mixed -effects model fit by maximum likelihood
## Data: Data1
## AIC BIC logLik
## 422.6504 457.8075 -196.3252
##
## Random effects:
## Formula: ~Days_of_NAC | Patient_Number
## Structure: General positive -definite , Log -Cholesky
parametrization
## StdDev Corr
## (Intercept) 3.9982256 (Intr) D__NAC
## Days_of_NACTP1 3.8263622 -0.680
## Days_of_NACTP5 5.2737579 -0.503 0.964
## Residual 0.7459079
##
## Fixed effects: HHb_N ~ Days_of_NAC * PCR_bin +
MenopausalStatus + molecularSubtype
## Value Std.Error DF t-value
## (Intercept) 5.400065 3.149255 39 1.714712
## Days_of_NACTP1 -6.036356 2.431055 39 -2.483020
## Days_of_NACTP5 -8.780362 3.361388 39 -2.612124
## PCR_bin -2.379558 1.528832 30 -1.556455
## MenopausalStatus -0.570587 0.983910 30 -0.579918
## molecularSubtype 1.713937 0.803889 30 2.132058
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## Days_of_NACTP1:PCR_bin 4.252061 1.526834 39 2.784887











## (Intr) Dy__NACTP1 Dy__NACTP5 PCR_bn
## Days_of_NACTP1 -0.510
## Days_of_NACTP5 -0.375 0.896
## PCR_bin -0.628 0.648 0.476
## MenopausalStatus -0.448 0.001 0.001 -0.075
## molecularSubtype -0.474 -0.043 -0.033 -0.136
## Days_of_NACTP1:PCR_bin 0.466 -0.950 -0.851 -0.673
## Days_of_NACTP5:PCR_bin 0.339 -0.845 -0.949 -0.493







## Days_of_NACTP1:PCR_bin 0.009 0.057
## Days_of_NACTP5:PCR_bin 0.004 0.048 0.890
##
## Standardized Within -Group Residuals:
## Min Q1 Med Q3




## Number of Observations: 77
## Number of Groups: 34
#PART II - Conditional growth model (mod5)
#STEP 1: Upload dataset for the 6 time -point study
library (" readxl ")
Data2 <- read_excel (" TP6_Long.xlsx", sheet =1)
Data2$Days_of_NAC <- factor(x = Data2$Days_of_NAC ,
labels = c("TP0", "TP1", "TP2", "TP3", "TP4", "TP5"))
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#STEP 2: Open "nlme" package
library(nlme)
# STEP 3: Conditional growth model
mod5 <- lme(HHb_N~Days_of_NAC*PCR_bin + molecularSubtype +
MenopausalStatus ,random =~ Days_of_NAC|Patient_Number ,data=Data2
,method ="ML", control=lmeControl(opt='optim '), na.action=na.
exclude)
# STEP 4: Displaying our results - Full model: 6 time points
summary(mod5)
## Linear mixed -effects model fit by maximum likelihood
## Data: Data2
## AIC BIC logLik
## 1064.949 1191.287 -496.4745
##
## Random effects:
## Formula: ~Days_of_NAC | Patient_Number
## Structure: General positive -definite , Log -Cholesky
parametrization
## StdDev Corr
## (Intercept) 2.2725476 (Intr) D__NACTP1 D__NACTP2
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## Days_of_NACTP1 0.7131177 -0.296
## Days_of_NACTP2 2.4538972 -0.777 0.501
## Days_of_NACTP3 2.9866012 -0.645 0.172 0.493
## Days_of_NACTP4 2.3375872 -0.048 0.311 0.280
## Days_of_NACTP5 2.3697224 -0.268 0.479 0.343
## Residual 0.6619238
##





## Days_of_NACTP5 0.594 0.688
## Residual
##
## Fixed effects: HHb_N ~ Days_of_NAC * PCR_bin +
molecularSubtype + MenopausalStatus
## Value Std.Error DF t-value
## (Intercept) 5.156102 1.3740785 185 3.752407
## Days_of_NACTP1 -3.233450 0.7027104 185 -4.601397
## Days_of_NACTP2 -3.399925 1.4155943 185 -2.401765
## Days_of_NACTP3 -1.185385 1.7897365 185 -0.662323
## Days_of_NACTP4 -3.641681 1.5183178 185 -2.398497
## Days_of_NACTP5 -3.493351 1.5705550 185 -2.224278
## PCR_bin -1.136143 0.7216765 48 -1.574311
## molecularSubtype 0.081072 0.2492526 48 0.325262
139
## MenopausalStatus 0.035564 0.3834739 48 0.092741
## Days_of_NACTP1:PCR_bin 1.925306 0.3970761 185 4.848706
## Days_of_NACTP2:PCR_bin 2.037167 0.8251029 185 2.468986
## Days_of_NACTP3:PCR_bin 0.832579 1.0297774 185 0.808504
## Days_of_NACTP4:PCR_bin 2.707908 0.8686174 185 3.117492

















## (Intr) Dy__NACTP1 Dy__NACTP2
## Days_of_NACTP1 -0.253
## Days_of_NACTP2 -0.674 0.355
## Days_of_NACTP3 -0.519 0.162 0.415
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## Days_of_NACTP4 -0.109 0.232 0.256
## Days_of_NACTP5 -0.238 0.270 0.289
## PCR_bin -0.813 0.273 0.700
## molecularSubtype -0.243 -0.002 0.033
## MenopausalStatus -0.335 -0.006 0.005
## Days_of_NACTP1:PCR_bin 0.251 -0.967 -0.352
## Days_of_NACTP2:PCR_bin 0.652 -0.341 -0.960
## Days_of_NACTP3:PCR_bin 0.505 -0.159 -0.405
## Days_of_NACTP4:PCR_bin 0.107 -0.228 -0.252
## Days_of_NACTP5:PCR_bin 0.234 -0.269 -0.284





## Days_of_NACTP5 0.497 0.535
## PCR_bin 0.566 0.093 0.251
## molecularSubtype -0.051 0.029 -0.006
## MenopausalStatus 0.030 0.023 0.015
## Days_of_NACTP1:PCR_bin -0.162 -0.231 -0.271
## Days_of_NACTP2:PCR_bin -0.400 -0.248 -0.278
## Days_of_NACTP3:PCR_bin -0.963 -0.413 -0.481
## Days_of_NACTP4:PCR_bin -0.415 -0.964 -0.521
## Days_of_NACTP5:PCR_bin -0.484 -0.523 -0.964









## MenopausalStatus 0.036 -0.178
## Days_of_NACTP1:PCR_bin -0.293 0.001 0.006
## Days_of_NACTP2:PCR_bin -0.729 -0.033 -0.018 0.366
## Days_of_NACTP3:PCR_bin -0.596 0.047 -0.028 0.172
## Days_of_NACTP4:PCR_bin -0.098 -0.031 -0.022 0.248
## Days_of_NACTP5:PCR_bin -0.266 0.004 -0.015 0.295












## Days_of_NACTP4:PCR_bin 0.264 0.432
## Days_of_NACTP5:PCR_bin 0.297 0.506 0.550
142
##
## Standardized Within -Group Residuals:
## Min Q1 Med Q3 Max
## -1.44439320 -0.26349373 -0.04167042 0.23550054 1.77504950
##
## Number of Observations: 247
## Number of Groups: 52
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Appendix C: Longitudinal Data Analysis Script and Output - Chapter 6
#STEP 1: Upload dataset for the 6 time -point
library (" readxl ")
Data1 <- read_excel (" DynTrace_tv_6TP_Long.xlsx", sheet =1)
Data1$Days_of_NAC <- factor(x = Data1$Days_of_NAC ,
labels = c("TP0", "TP1","TP2", "TP3", "TP4", "TP5"))
Data1$molecularSubtype <- factor(x = Data1$molecularSubtype ,
labels = c("TNBC", "HER2+","HR+/HER2 -" ))
Data1$PCR_bin <- factor(x = Data1$PCR_bin , labels = c("pCR", "non
-pCR"))
#STEP 2: Open "nlme" package
library(nlme)
# STEP 3: Conditional growth model
# f1: Washout slope
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mod_f1 <- lme(f1~Days_of_NAC*PCR_bin + molecularSubtype + Age +
BMI ,random =~ Days_of_NAC|Patient_Number ,data=Data1 ,method ="ML",
control=lmeControl(opt='optim '), na.action=na.exclude)
# STEP 4: Displaying results - Full model: 6 time points
summary(mod_f1)
## Linear mixed -effects model fit by maximum likelihood
## Data: Data1
## AIC BIC logLik
## 1135.321 1265.803 -529.6605
##
## Random effects:
## Formula: ~Days_of_NAC | Patient_Number
## Structure: General positive -definite , Log -Cholesky
parametrization
## StdDev Corr
## (Intercept) 7.0584249 (Intr) D__NACTP1 D__NACTP2
## Days_of_NACTP1 6.7407392 -0.979
## Days_of_NACTP2 6.1498998 -0.941 0.941
## Days_of_NACTP3 3.8588618 -0.919 0.891 0.912
## Days_of_NACTP4 6.8085873 -0.884 0.859 0.849
## Days_of_NACTP5 4.7305502 -0.926 0.916 0.774
## Residual 0.7335448
##






## Days_of_NACTP5 0.842 0.755
## Residual
##
## Fixed effects: f1 ~ Days_of_NAC * PCR_bin + molecularSubtype +
Age + BMI
## Value Std.Error DF
## (Intercept) 5.708390 2.1580976 164
## Days_of_NACTP1 -2.722952 1.8908046 164
## Days_of_NACTP2 -2.976805 1.7299101 164
## Days_of_NACTP3 -1.312700 1.2179782 164
## Days_of_NACTP4 -1.984901 1.8981129 164
## Days_of_NACTP5 -1.917858 1.3943062 164
## PCR_binnon -pCR 0.345388 2.3530351 49
## molecularSubtypeHER2+ 0.402620 0.5479272 49
## molecularSubtypeHR +/HER2 - 0.228193 0.5068451 49
## Age -0.002369 0.0168613 49
## BMI -0.060533 0.0281334 49
## Days_of_NACTP1:PCR_binnon -pCR -0.173477 2.3085876 164
## Days_of_NACTP2:PCR_binnon -pCR 0.413507 2.1311960 164
## Days_of_NACTP3:PCR_binnon -pCR -1.238910 1.4898316 164
## Days_of_NACTP4:PCR_binnon -pCR -0.091859 2.3391233 164
## Days_of_NACTP5:PCR_binnon -pCR -0.394236 1.6972285 164
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## t-value p-value
## (Intercept) 2.6451030 0.0090
## Days_of_NACTP1 -1.4401023 0.1517
## Days_of_NACTP2 -1.7207861 0.0872
## Days_of_NACTP3 -1.0777694 0.2827
## Days_of_NACTP4 -1.0457236 0.2972
## Days_of_NACTP5 -1.3754929 0.1709
## PCR_binnon -pCR 0.1467841 0.8839
## molecularSubtypeHER2+ 0.7348065 0.4660
## molecularSubtypeHR +/HER2 - 0.4502232 0.6545
## Age -0.1405050 0.8888
## BMI -2.1516307 0.0364
## Days_of_NACTP1:PCR_binnon -pCR -0.0751442 0.9402
## Days_of_NACTP2:PCR_binnon -pCR 0.1940257 0.8464
## Days_of_NACTP3:PCR_binnon -pCR -0.8315769 0.4069
## Days_of_NACTP4:PCR_binnon -pCR -0.0392706 0.9687
## Days_of_NACTP5:PCR_binnon -pCR -0.2322821 0.8166
## Correlation:
## (Intr) Dy__NACTP1 Dy__NACTP2
## Days_of_NACTP1 -0.820
## Days_of_NACTP2 -0.787 0.930
## Days_of_NACTP3 -0.712 0.854 0.881
## Days_of_NACTP4 -0.736 0.858 0.846
## Days_of_NACTP5 -0.753 0.887 0.784
## PCR_binnon -pCR -0.697 0.787 0.759
## molecularSubtypeHER2+ -0.033 -0.091 -0.079
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## molecularSubtypeHR +/HER2 - 0.006 0.016 0.038
## Age -0.323 -0.069 -0.080
## BMI -0.318 -0.035 -0.042
## Days_of_NACTP1:PCR_binnon -pCR 0.675 -0.818 -0.760
## Days_of_NACTP2:PCR_binnon -pCR 0.639 -0.754 -0.810
## Days_of_NACTP3:PCR_binnon -pCR 0.585 -0.698 -0.719
## Days_of_NACTP4:PCR_binnon -pCR 0.594 -0.695 -0.685






## Days_of_NACTP5 0.829 0.757
## PCR_binnon -pCR 0.709 0.717
## molecularSubtypeHER2+ -0.118 -0.083
## molecularSubtypeHR +/HER2 - 0.038 0.015
## Age -0.100 -0.070
## BMI -0.074 -0.054
## Days_of_NACTP1:PCR_binnon -pCR -0.698 -0.701
## Days_of_NACTP2:PCR_binnon -pCR -0.713 -0.686
## Days_of_NACTP3:PCR_binnon -pCR -0.816 -0.612
## Days_of_NACTP4:PCR_binnon -pCR -0.607 -0.811
## Days_of_NACTP5:PCR_binnon -pCR -0.678 -0.620







## PCR_binnon -pCR 0.729
## molecularSubtypeHER2+ -0.105 -0.074
## molecularSubtypeHR +/HER2 - 0.053 -0.053 0.554
## Age -0.065 -0.015 -0.020
## BMI -0.068 -0.020 -0.029
## Days_of_NACTP1:PCR_binnon -pCR -0.725 -0.970 0.078
## Days_of_NACTP2:PCR_binnon -pCR -0.634 -0.936 0.069
## Days_of_NACTP3:PCR_binnon -pCR -0.676 -0.877 0.101
## Days_of_NACTP4:PCR_binnon -pCR -0.612 -0.879 0.070
## Days_of_NACTP5:PCR_binnon -pCR -0.818 -0.901 0.086








## molecularSubtypeHR +/HER2 -
## Age -0.187
## BMI -0.223 0.011
## Days_of_NACTP1:PCR_binnon -pCR 0.003 0.061 0.007
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## Days_of_NACTP2:PCR_binnon -pCR -0.011 0.065 0.024
## Days_of_NACTP3:PCR_binnon -pCR -0.015 0.090 0.036
## Days_of_NACTP4:PCR_binnon -pCR 0.009 0.063 0.036













## Days_of_NACTP2:PCR_binnon -pCR 0.931
## Days_of_NACTP3:PCR_binnon -pCR 0.856 0.881
## Days_of_NACTP4:PCR_binnon -pCR 0.854 0.843
















## Days_of_NACTP4:PCR_binnon -pCR 0.749
## Days_of_NACTP5:PCR_binnon -pCR 0.830 0.753
##
## Standardized Within -Group Residuals:
## Min Q1 Med Q3 Max
## -1.72194470 -0.15112691 -0.05257972 0.14654240 2.17097212
##
## Number of Observations: 229
## Number of Groups: 55
# STEP 5: Repeat for all the other features
#f2: Slope at the steepest part of the breath hold (ascending)
curve
mod_f2 <- lme(f2~Days_of_NAC*PCR_bin + molecularSubtype + Age +
BMI , random =~ Days_of_NAC|Patient_Number ,data=Data1 ,method ="ML
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", control=lmeControl(opt='optim '), na.action=na.exclude)
summary(mod_f2)
## Linear mixed -effects model fit by maximum likelihood
## Data: Data1
## AIC BIC logLik
## 1854.228 1984.71 -889.1141
##
## Random effects:
## Formula: ~Days_of_NAC | Patient_Number
## Structure: General positive -definite , Log -Cholesky
parametrization
## StdDev Corr
## (Intercept) 10.660137 (Intr) D__NACTP1 D__NACTP2
## Days_of_NACTP1 16.047105 -0.835
## Days_of_NACTP2 8.828959 -0.133 0.441
## Days_of_NACTP3 23.527580 -0.619 0.628 0.078
## Days_of_NACTP4 18.275542 -0.609 0.482 0.014
## Days_of_NACTP5 12.994921 -0.832 0.828 0.080
## Residual 3.833010
##






## Days_of_NACTP5 0.684 0.607
## Residual
##
## Fixed effects: f2 ~ Days_of_NAC * PCR_bin + molecularSubtype +
Age + BMI
## Value Std.Error DF
## (Intercept) 35.39898 6.916569 164
## Days_of_NACTP1 -0.58794 4.807108 164
## Days_of_NACTP2 7.15930 3.323807 164
## Days_of_NACTP3 22.18808 6.820824 164
## Days_of_NACTP4 10.26248 5.342585 164
## Days_of_NACTP5 3.64803 4.180142 164
## PCR_binnon -pCR 6.05465 4.360808 49
## molecularSubtypeHER2+ 2.05049 2.796815 49
## molecularSubtypeHR +/HER2 - -3.56050 2.435977 49
## Age 0.06905 0.084266 49
## BMI -0.48421 0.131514 49
## Days_of_NACTP1:PCR_binnon -pCR -1.55155 5.873044 164
## Days_of_NACTP2:PCR_binnon -pCR -6.94827 4.203858 164
## Days_of_NACTP3:PCR_binnon -pCR -20.96337 8.339379 164
## Days_of_NACTP4:PCR_binnon -pCR -10.23277 6.638917 164
## Days_of_NACTP5:PCR_binnon -pCR -3.56360 5.135225 164
## t-value p-value
## (Intercept) 5.117997 0.0000
## Days_of_NACTP1 -0.122306 0.9028
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## Days_of_NACTP2 2.153944 0.0327
## Days_of_NACTP3 3.252991 0.0014
## Days_of_NACTP4 1.920883 0.0565
## Days_of_NACTP5 0.872704 0.3841
## PCR_binnon -pCR 1.388423 0.1713
## molecularSubtypeHER2+ 0.733151 0.4670
## molecularSubtypeHR +/HER2 - -1.461630 0.1502
## Age 0.819387 0.4165
## BMI -3.681845 0.0006
## Days_of_NACTP1:PCR_binnon -pCR -0.264182 0.7920
## Days_of_NACTP2:PCR_binnon -pCR -1.652832 0.1003
## Days_of_NACTP3:PCR_binnon -pCR -2.513781 0.0129
## Days_of_NACTP4:PCR_binnon -pCR -1.541331 0.1252
## Days_of_NACTP5:PCR_binnon -pCR -0.693953 0.4887
## Correlation:
## (Intr) Dy__NACTP1 Dy__NACTP2
## Days_of_NACTP1 -0.460
## Days_of_NACTP2 -0.307 0.514
## Days_of_NACTP3 -0.349 0.575 0.224
## Days_of_NACTP4 -0.359 0.529 0.257
## Days_of_NACTP5 -0.500 0.739 0.343
## PCR_binnon -pCR -0.498 0.662 0.369
## molecularSubtypeHER2+ -0.191 -0.009 0.069
## molecularSubtypeHR +/HER2 - 0.031 -0.059 -0.037
## Age -0.641 0.051 0.060
## BMI -0.551 0.049 0.079
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## Days_of_NACTP1:PCR_binnon -pCR 0.373 -0.817 -0.420
## Days_of_NACTP2:PCR_binnon -pCR 0.238 -0.405 -0.788
## Days_of_NACTP3:PCR_binnon -pCR 0.288 -0.469 -0.183
## Days_of_NACTP4:PCR_binnon -pCR 0.273 -0.424 -0.205






## Days_of_NACTP5 0.623 0.613
## PCR_binnon -pCR 0.498 0.536
## molecularSubtypeHER2+ 0.019 0.014
## molecularSubtypeHR +/HER2 - -0.042 -0.057
## Age 0.055 0.046
## BMI 0.024 0.014
## Days_of_NACTP1:PCR_binnon -pCR -0.470 -0.432
## Days_of_NACTP2:PCR_binnon -pCR -0.177 -0.202
## Days_of_NACTP3:PCR_binnon -pCR -0.818 -0.397
## Days_of_NACTP4:PCR_binnon -pCR -0.391 -0.804
## Days_of_NACTP5:PCR_binnon -pCR -0.507 -0.499







## PCR_binnon -pCR 0.664
## molecularSubtypeHER2+ 0.058 0.031
## molecularSubtypeHR +/HER2 - -0.006 -0.157 0.559
## Age 0.109 0.180 -0.032
## BMI 0.032 0.006 0.003
## Days_of_NACTP1:PCR_binnon -pCR -0.605 -0.812 -0.004
## Days_of_NACTP2:PCR_binnon -pCR -0.272 -0.464 -0.060
## Days_of_NACTP3:PCR_binnon -pCR -0.511 -0.607 -0.028
## Days_of_NACTP4:PCR_binnon -pCR -0.493 -0.644 -0.023
## Days_of_NACTP5:PCR_binnon -pCR -0.815 -0.809 -0.067








## molecularSubtypeHR +/HER2 -
## Age -0.145
## BMI -0.212 0.012
## Days_of_NACTP1:PCR_binnon -pCR 0.028 -0.045 -0.023
## Days_of_NACTP2:PCR_binnon -pCR 0.006 -0.064 -0.029
## Days_of_NACTP3:PCR_binnon -pCR 0.014 -0.053 -0.008
## Days_of_NACTP4:PCR_binnon -pCR 0.031 -0.036 0.021
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## Days_of_NACTP2:PCR_binnon -pCR 0.525
## Days_of_NACTP3:PCR_binnon -pCR 0.590 0.239
## Days_of_NACTP4:PCR_binnon -pCR 0.524 0.265
















## Days_of_NACTP4:PCR_binnon -pCR 0.481
## Days_of_NACTP5:PCR_binnon -pCR 0.628 0.605
##
## Standardized Within -Group Residuals:
## Min Q1 Med Q3 Max
## -0.96954636 -0.24077357 -0.05734928 0.20872070 1.15358928
##
## Number of Observations: 229
## Number of Groups: 55
#f3: Point of inflection in the breath hold (decending) response
curve
mod_f3 <- lme(f3~Days_of_NAC*PCR_bin + molecularSubtype + Age +
BMI , ,random =~ Days_of_NAC|Patient_Number ,data=Data1 ,method ="ML
", control=lmeControl(opt='optim '), na.action=na.exclude)
summary(mod_f3)
## Linear mixed -effects model fit by maximum likelihood
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## Data: Data1
## AIC BIC logLik
## 859.7355 990.217 -391.8678
##
## Random effects:
## Formula: ~Days_of_NAC | Patient_Number
## Structure: General positive -definite , Log -Cholesky
parametrization
## StdDev Corr
## (Intercept) 0.6758220 (Intr) D__NACTP1 D__NACTP2
## Days_of_NACTP1 1.0512502 -0.752
## Days_of_NACTP2 1.7599680 -0.460 0.252
## Days_of_NACTP3 2.6643254 0.278 0.140 -0.115
## Days_of_NACTP4 2.0981010 -0.275 -0.010 0.083
## Days_of_NACTP5 0.8788950 -0.360 0.152 0.091
## Residual 0.4243905
##





## Days_of_NACTP5 -0.105 -0.030
## Residual
##
## Fixed effects: f3 ~ Days_of_NAC * PCR_bin + molecularSubtype +
159
Age + BMI
## Value Std.Error DF
## (Intercept) 3.702089 0.5165509 164
## Days_of_NACTP1 0.161425 0.3611208 164
## Days_of_NACTP2 0.769107 0.5201801 164
## Days_of_NACTP3 2.415317 0.7876579 164
## Days_of_NACTP4 1.118096 0.6017006 164
## Days_of_NACTP5 0.229285 0.3494326 164
## PCR_binnon -pCR 0.303791 0.3353342 49
## molecularSubtypeHER2+ 0.353042 0.1924980 49
## molecularSubtypeHR +/HER2 - -0.412165 0.1784317 49
## Age -0.003909 0.0058970 49
## BMI -0.005616 0.0096257 49
## Days_of_NACTP1:PCR_binnon -pCR -0.144816 0.4402060 164
## Days_of_NACTP2:PCR_binnon -pCR -0.758676 0.6411746 164
## Days_of_NACTP3:PCR_binnon -pCR -1.680173 0.9602536 164
## Days_of_NACTP4:PCR_binnon -pCR -0.699633 0.7505207 164
## Days_of_NACTP5:PCR_binnon -pCR -0.006532 0.4286380 164
## t-value p-value
## (Intercept) 7.166940 0.0000
## Days_of_NACTP1 0.447011 0.6555
## Days_of_NACTP2 1.478540 0.1412
## Days_of_NACTP3 3.066455 0.0025
## Days_of_NACTP4 1.858226 0.0649
## Days_of_NACTP5 0.656162 0.5126
## PCR_binnon -pCR 0.905936 0.3694
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## molecularSubtypeHER2+ 1.834004 0.0727
## molecularSubtypeHR +/HER2 - -2.309934 0.0251
## Age -0.662945 0.5105
## BMI -0.583425 0.5623
## Days_of_NACTP1:PCR_binnon -pCR -0.328974 0.7426
## Days_of_NACTP2:PCR_binnon -pCR -1.183259 0.2384
## Days_of_NACTP3:PCR_binnon -pCR -1.749718 0.0820
## Days_of_NACTP4:PCR_binnon -pCR -0.932197 0.3526
## Days_of_NACTP5:PCR_binnon -pCR -0.015240 0.9879
## Correlation:
## (Intr) Dy__NACTP1 Dy__NACTP2
## Days_of_NACTP1 -0.445
## Days_of_NACTP2 -0.333 0.378
## Days_of_NACTP3 -0.068 0.194 0.019
## Days_of_NACTP4 -0.231 0.209 0.196
## Days_of_NACTP5 -0.396 0.403 0.271
## PCR_binnon -pCR -0.531 0.621 0.439
## molecularSubtypeHER2+ -0.194 -0.046 0.049
## molecularSubtypeHR +/HER2 - 0.050 -0.094 -0.006
## Age -0.630 0.022 0.021
## BMI -0.571 0.094 0.061
## Days_of_NACTP1:PCR_binnon -pCR 0.366 -0.818 -0.309
## Days_of_NACTP2:PCR_binnon -pCR 0.260 -0.302 -0.810
## Days_of_NACTP3:PCR_binnon -pCR 0.063 -0.160 -0.016
## Days_of_NACTP4:PCR_binnon -pCR 0.161 -0.163 -0.155







## Days_of_NACTP5 0.100 0.165
## PCR_binnon -pCR 0.037 0.339
## molecularSubtypeHER2+ 0.092 -0.001
## molecularSubtypeHR +/HER2 - 0.016 -0.057
## Age 0.047 0.021
## BMI 0.020 0.023
## Days_of_NACTP1:PCR_binnon -pCR -0.160 -0.170
## Days_of_NACTP2:PCR_binnon -pCR -0.017 -0.158
## Days_of_NACTP3:PCR_binnon -pCR -0.820 -0.174
## Days_of_NACTP4:PCR_binnon -pCR -0.171 -0.802
## Days_of_NACTP5:PCR_binnon -pCR -0.085 -0.134






## PCR_binnon -pCR 0.466
## molecularSubtypeHER2+ 0.052 0.051
## molecularSubtypeHR +/HER2 - 0.009 -0.149 0.611
## Age 0.099 0.190 -0.001
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## BMI 0.066 0.038 -0.053
## Days_of_NACTP1:PCR_binnon -pCR -0.332 -0.767 0.023
## Days_of_NACTP2:PCR_binnon -pCR -0.220 -0.534 -0.054
## Days_of_NACTP3:PCR_binnon -pCR -0.083 -0.038 -0.071
## Days_of_NACTP4:PCR_binnon -pCR -0.130 -0.407 -0.009
## Days_of_NACTP5:PCR_binnon -pCR -0.817 -0.574 -0.067








## molecularSubtypeHR +/HER2 -
## Age -0.148
## BMI -0.246 0.045
## Days_of_NACTP1:PCR_binnon -pCR 0.058 -0.029 -0.060
## Days_of_NACTP2:PCR_binnon -pCR -0.009 -0.033 -0.009
## Days_of_NACTP3:PCR_binnon -pCR -0.017 -0.038 -0.031
## Days_of_NACTP4:PCR_binnon -pCR 0.042 -0.022 0.034














## Days_of_NACTP2:PCR_binnon -pCR 0.374
## Days_of_NACTP3:PCR_binnon -pCR 0.212 0.016
## Days_of_NACTP4:PCR_binnon -pCR 0.190 0.188
















## Days_of_NACTP4:PCR_binnon -pCR 0.203
## Days_of_NACTP5:PCR_binnon -pCR 0.101 0.162
##
## Standardized Within -Group Residuals:
## Min Q1 Med Q3 Max
## -1.74949506 -0.17782682 -0.04697488 0.12153216 1.70706485
##
## Number of Observations: 229
## Number of Groups: 55
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